FALSE2020FY00007641800.33330.3333nonous_gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus_gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus_gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus_gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus_gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus_gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus_gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus_gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus_gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus_gaap:FairValueMeasuredAtNetAssetValuePerShareMember2111100007641802020-01-012020-12-310000764180mo:CommonStock0.3313ParValueMember2020-01-012020-12-310000764180mo:CommonStock1.000NotesDue2023Member2020-01-012020-12-310000764180mo:CommonStock1.700NotesDue2025Member2020-01-012020-12-310000764180mo:CommonStock2.200NotesDue2027Member2020-01-012020-12-310000764180mo:CommonStock3.125NotesDue2031Member2020-01-012020-12-31iso4217:USD00007641802020-06-30xbrli:shares00007641802021-02-1500007641802020-12-3100007641802019-12-31iso4217:USDxbrli:shares00007641802019-01-012019-12-3100007641802018-01-012018-12-3100007641802018-12-3100007641802017-12-310000764180us-gaap:CommonStockMember2017-12-310000764180us-gaap:AdditionalPaidInCapitalMember2017-12-310000764180us-gaap:RetainedEarningsMember2017-12-310000764180us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-12-310000764180us-gaap:TreasuryStockMember2017-12-310000764180us-gaap:NoncontrollingInterestMember2017-12-310000764180us-gaap:RetainedEarningsMember2018-01-012018-12-310000764180us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-01-012018-12-310000764180us-gaap:AdditionalPaidInCapitalMember2018-01-012018-12-310000764180us-gaap:TreasuryStockMember2018-01-012018-12-310000764180us-gaap:NoncontrollingInterestMember2018-01-012018-12-310000764180us-gaap:CommonStockMember2018-12-310000764180us-gaap:AdditionalPaidInCapitalMember2018-12-310000764180us-gaap:RetainedEarningsMember2018-12-310000764180us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310000764180us-gaap:TreasuryStockMember2018-12-310000764180us-gaap:NoncontrollingInterestMember2018-12-310000764180us-gaap:RetainedEarningsMember2019-01-012019-12-310000764180us-gaap:NoncontrollingInterestMember2019-01-012019-12-310000764180us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310000764180us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310000764180us-gaap:TreasuryStockMember2019-01-012019-12-310000764180us-gaap:CommonStockMember2019-12-310000764180us-gaap:AdditionalPaidInCapitalMember2019-12-310000764180us-gaap:RetainedEarningsMember2019-12-310000764180us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000764180us-gaap:TreasuryStockMember2019-12-310000764180us-gaap:NoncontrollingInterestMember2019-12-310000764180us-gaap:RetainedEarningsMember2020-01-012020-12-310000764180us-gaap:NoncontrollingInterestMember2020-01-012020-12-310000764180us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310000764180us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310000764180us-gaap:TreasuryStockMember2020-01-012020-12-310000764180us-gaap:CommonStockMember2020-12-310000764180us-gaap:AdditionalPaidInCapitalMember2020-12-310000764180us-gaap:RetainedEarningsMember2020-12-310000764180us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000764180us-gaap:TreasuryStockMember2020-12-310000764180us-gaap:NoncontrollingInterestMember2020-12-31xbrli:pure0000764180mo:HelixInnovationsLLCMember2020-12-310000764180mo:HelixInnovationsLLCMember2019-12-310000764180mo:HelixInnovationsLLCMember2019-01-012019-12-310000764180mo:ABInBevMember2020-12-310000764180mo:JUULMember2018-12-310000764180mo:JUULMember2020-12-310000764180mo:CronosGroupInc.Member2019-03-310000764180mo:CronosGroupInc.Member2020-12-310000764180srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2020-01-012020-12-310000764180srt:MaximumMemberus-gaap:BuildingAndBuildingImprovementsMember2020-01-012020-12-310000764180srt:MaximumMember2020-01-012020-12-310000764180mo:USSTCMember2020-01-012020-12-310000764180mo:Ste.MichelleMember2020-01-012020-12-310000764180mo:SmokeableProductsSegmentMember2020-12-310000764180mo:SmokeableProductsSegmentMember2019-12-310000764180mo:OralTobaccoSegmentMember2020-12-310000764180mo:OralTobaccoSegmentMember2019-12-310000764180mo:WineSegmentMember2020-12-310000764180mo:WineSegmentMember2019-12-310000764180us-gaap:AllOtherSegmentsMember2020-12-310000764180us-gaap:AllOtherSegmentsMember2019-12-310000764180mo:USTLitigationMember2020-12-310000764180mo:MiddletonMember2020-12-310000764180mo:DefiniteLivedIntangibleAssetsMembersrt:WeightedAverageMember2020-01-012020-12-310000764180mo:WineSegmentMember2019-01-012019-12-310000764180us-gaap:TrademarksMember2018-01-012018-12-310000764180us-gaap:OperatingSegmentsMembermo:SmokeableProductsSegmentMember2020-01-012020-12-310000764180us-gaap:OperatingSegmentsMembermo:SmokeableProductsSegmentMember2019-01-012019-12-310000764180us-gaap:OperatingSegmentsMembermo:SmokeableProductsSegmentMember2018-01-012018-12-310000764180us-gaap:OperatingSegmentsMembermo:OralTobaccoSegmentMember2020-01-012020-12-310000764180us-gaap:OperatingSegmentsMembermo:OralTobaccoSegmentMember2019-01-012019-12-310000764180us-gaap:OperatingSegmentsMembermo:OralTobaccoSegmentMember2018-01-012018-12-310000764180mo:WineSegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310000764180mo:WineSegmentMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310000764180mo:WineSegmentMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310000764180us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2020-01-012020-12-310000764180us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2019-01-012019-12-310000764180us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2018-01-012018-12-310000764180us-gaap:CorporateNonSegmentMember2020-01-012020-12-310000764180us-gaap:CorporateNonSegmentMember2019-01-012019-12-310000764180us-gaap:CorporateNonSegmentMember2018-01-012018-12-310000764180us-gaap:CostOfSalesMember2019-01-012019-12-310000764180mo:MarketingAdministrationAndResearchCostsMember2019-01-012019-12-310000764180mo:WineBusinessStrategicResetMember2020-01-012020-12-310000764180mo:InventoryWriteOffMembermo:WineBusinessStrategicResetMember2020-01-012020-03-310000764180mo:WineBusinessStrategicResetMemberus-gaap:PurchaseCommitmentMember2020-01-012020-03-310000764180mo:WineBusinessStrategicResetMembermo:InventoryDisposalCostsAndOtherMember2020-01-012020-12-310000764180mo:WineBusinessStrategicResetMemberus-gaap:PurchaseCommitmentMember2020-01-012020-12-310000764180mo:RefocusofInnovativeProductEffortsMember2019-01-012019-12-310000764180mo:RefocusofInnovativeProductEffortsMember2018-01-012018-12-310000764180mo:AssetImpairmentandExitCostsMembermo:RefocusofInnovativeProductEffortsMember2018-01-012018-12-310000764180us-gaap:OtherRestructuringMembermo:RefocusofInnovativeProductEffortsMember2018-01-012018-12-310000764180mo:CostReductionProgramMember2020-12-310000764180mo:CostReductionProgramMember2020-01-012020-12-310000764180mo:CostReductionProgramMember2019-01-012019-12-310000764180mo:CostReductionProgramMember2018-01-012018-12-310000764180us-gaap:EmployeeSeveranceMembermo:CostReductionProgramMember2020-12-310000764180us-gaap:OtherRestructuringMembermo:CostReductionProgramMember2020-12-310000764180mo:CostReductionProgramMember2018-12-012020-12-310000764180mo:ABInBevMember2019-12-310000764180mo:JUULMember2019-12-310000764180mo:CronosGroupInc.Member2019-12-310000764180us-gaap:CommonStockMembermo:CronosGroupInc.Member2020-12-310000764180mo:EquityContractWarrantMembermo:CronosGroupInc.Member2020-12-310000764180mo:EquityContractPreemptiveRIghtsMembermo:CronosGroupInc.Member2020-12-310000764180us-gaap:CommonStockMembermo:CronosGroupInc.Member2019-12-310000764180mo:EquityContractWarrantMembermo:CronosGroupInc.Member2019-12-310000764180mo:EquityContractPreemptiveRIghtsMembermo:CronosGroupInc.Member2019-12-310000764180mo:ABInBevMember2020-01-012020-12-310000764180mo:ABInBevMember2019-01-012019-12-310000764180mo:ABInBevMember2018-01-012018-12-310000764180mo:CronosGroupInc.Member2020-01-012020-12-310000764180mo:CronosGroupInc.Member2019-01-012019-12-310000764180mo:CronosGroupInc.Member2018-01-012018-12-310000764180mo:JUULMember2020-01-012020-12-310000764180mo:JUULMember2019-01-012019-12-310000764180mo:JUULMember2018-01-012018-12-310000764180mo:ABInBevMember2020-01-012020-12-310000764180mo:ABInBevMember2019-01-012019-12-310000764180mo:ABInBevMember2018-01-012018-12-310000764180mo:ABInBevMember2020-09-300000764180mo:ABInBevMember2019-09-300000764180us-gaap:FairValueInputsLevel1Membermo:ABInBevMember2020-12-310000764180us-gaap:FairValueInputsLevel1Membermo:ABInBevMember2019-12-310000764180mo:ABInBevMember2020-12-012020-12-310000764180mo:JUULMember2018-12-012018-12-310000764180mo:JUULMember2020-01-012020-01-310000764180mo:JUULMember2020-01-31mo:director0000764180mo:EquityMethodInvestmentsFairValueOptionMember2019-12-310000764180mo:EquityMethodInvestmentsFairValueOptionMember2020-01-012020-12-310000764180mo:EquityMethodInvestmentsFairValueOptionMember2020-12-3100007641802020-11-200000764180mo:JUULMember2020-10-012020-12-310000764180mo:JUULMember2019-07-012019-09-300000764180mo:JUULMember2019-10-012019-12-31iso4217:CADxbrli:shares0000764180mo:EquityContractPreemptiveRIghtsMembermo:CronosGroupInc.Member2019-03-310000764180mo:EquityContractWarrantMembermo:CronosGroupInc.Member2019-03-31iso4217:CAD0000764180mo:CronosGroupInc.Member2019-03-312019-03-310000764180mo:EquityContractWarrantMembermo:CronosGroupInc.Member2019-03-312019-03-310000764180mo:EquityContractPreemptiveRIghtsMembermo:CronosGroupInc.Member2019-03-312019-03-310000764180mo:EquityContractWarrantMembermo:CronosGroupInc.Member2020-01-012020-12-310000764180mo:EquityContractPreemptiveRIghtsMembermo:CronosGroupInc.Member2020-01-012020-12-31mo:board_member0000764180us-gaap:EquityMethodInvestmentsMembermo:CronosGroupInc.Member2020-01-012020-12-310000764180us-gaap:EquityMethodInvestmentsMembermo:CronosGroupInc.Member2019-01-012019-12-310000764180us-gaap:EquityMethodInvestmentsMembermo:CronosGroupInc.Member2020-09-300000764180us-gaap:EquityMethodInvestmentsMembermo:CronosGroupInc.Member2019-09-300000764180us-gaap:FairValueInputsLevel1Membermo:CronosGroupInc.Member2020-12-310000764180us-gaap:FairValueInputsLevel1Membermo:CronosGroupInc.Member2019-12-310000764180us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2020-12-310000764180us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2019-12-310000764180mo:ForeignCurrencyDenominatedDebtMember2020-12-310000764180mo:ForeignCurrencyDenominatedDebtMember2019-12-310000764180mo:EquityContractPreemptiveRIghtsMemberus-gaap:MeasurementInputSharePriceMember2020-12-310000764180mo:EquityContractPreemptiveRIghtsMemberus-gaap:MeasurementInputSharePriceMember2019-12-310000764180mo:EquityContractWarrantMemberus-gaap:MeasurementInputSharePriceMember2020-12-310000764180mo:EquityContractWarrantMemberus-gaap:MeasurementInputSharePriceMember2019-12-31mo:year0000764180mo:EquityContractPreemptiveRIghtsMemberus-gaap:MeasurementInputExpectedTermMember2020-12-310000764180mo:EquityContractPreemptiveRIghtsMemberus-gaap:MeasurementInputExpectedTermMember2019-12-310000764180mo:EquityContractWarrantMemberus-gaap:MeasurementInputExpectedTermMember2020-12-310000764180mo:EquityContractWarrantMemberus-gaap:MeasurementInputExpectedTermMember2019-12-310000764180us-gaap:MeasurementInputPriceVolatilityMembermo:EquityContractPreemptiveRIghtsMember2020-12-310000764180us-gaap:MeasurementInputPriceVolatilityMembermo:EquityContractPreemptiveRIghtsMember2019-12-310000764180mo:EquityContractWarrantMemberus-gaap:MeasurementInputPriceVolatilityMember2020-12-310000764180mo:EquityContractWarrantMemberus-gaap:MeasurementInputPriceVolatilityMember2019-12-310000764180us-gaap:MeasurementInputRiskFreeInterestRateMembermo:EquityContractPreemptiveRIghtsMember2020-12-310000764180us-gaap:MeasurementInputRiskFreeInterestRateMembermo:EquityContractPreemptiveRIghtsMember2019-12-310000764180mo:EquityContractWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2020-12-310000764180mo:EquityContractWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2019-12-310000764180mo:EquityContractPreemptiveRIghtsMemberus-gaap:MeasurementInputExpectedDividendRateMember2020-12-310000764180mo:EquityContractPreemptiveRIghtsMemberus-gaap:MeasurementInputExpectedDividendRateMember2019-12-310000764180mo:EquityContractWarrantMemberus-gaap:MeasurementInputExpectedDividendRateMember2020-12-310000764180mo:EquityContractWarrantMemberus-gaap:MeasurementInputExpectedDividendRateMember2019-12-310000764180srt:MinimumMembermo:MeasurementInputWeightedAverageExpectedTermMembermo:EquityContractPreemptiveRIghtsMember2020-12-310000764180srt:MaximumMembermo:MeasurementInputWeightedAverageExpectedTermMembermo:EquityContractPreemptiveRIghtsMember2020-12-310000764180srt:MinimumMembermo:MeasurementInputWeightedAverageExpectedTermMembermo:EquityContractPreemptiveRIghtsMember2019-12-310000764180srt:MaximumMembermo:MeasurementInputWeightedAverageExpectedTermMembermo:EquityContractPreemptiveRIghtsMember2019-12-310000764180srt:MinimumMemberus-gaap:MeasurementInputRiskFreeInterestRateMembermo:EquityContractPreemptiveRIghtsMember2020-12-310000764180srt:MaximumMemberus-gaap:MeasurementInputRiskFreeInterestRateMembermo:EquityContractPreemptiveRIghtsMember2020-12-310000764180srt:MinimumMemberus-gaap:MeasurementInputRiskFreeInterestRateMembermo:EquityContractPreemptiveRIghtsMember2019-12-310000764180srt:MaximumMemberus-gaap:MeasurementInputRiskFreeInterestRateMembermo:EquityContractPreemptiveRIghtsMember2019-12-310000764180us-gaap:FairValueInputsLevel3Memberus-gaap:EquityContractMember2019-12-310000764180us-gaap:FairValueInputsLevel3Memberus-gaap:EquityContractMember2018-12-310000764180us-gaap:FairValueInputsLevel3Memberus-gaap:EquityContractMember2020-01-012020-12-310000764180us-gaap:FairValueInputsLevel3Memberus-gaap:EquityContractMember2019-01-012019-12-310000764180us-gaap:FairValueInputsLevel3Memberus-gaap:EquityContractMember2020-12-310000764180us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000764180us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000764180mo:OtherAccruedLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000764180mo:OtherAccruedLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000764180us-gaap:OtherAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000764180us-gaap:OtherAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000764180us-gaap:ForeignExchangeContractMemberus-gaap:OtherLiabilitiesMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000764180us-gaap:ForeignExchangeContractMemberus-gaap:OtherLiabilitiesMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000764180us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000764180us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000764180mo:EquityContractWarrantMemberus-gaap:NondesignatedMembermo:InvestmentsInEquitySecuritiesMemberus-gaap:NetInvestmentHedgingMember2020-12-310000764180mo:EquityContractWarrantMemberus-gaap:NondesignatedMembermo:InvestmentsInEquitySecuritiesMemberus-gaap:NetInvestmentHedgingMember2019-12-310000764180us-gaap:NondesignatedMembermo:InvestmentsInEquitySecuritiesMembermo:EquityContractPreemptiveRIghtsMemberus-gaap:NetInvestmentHedgingMember2020-12-310000764180us-gaap:NondesignatedMembermo:InvestmentsInEquitySecuritiesMembermo:EquityContractPreemptiveRIghtsMemberus-gaap:NetInvestmentHedgingMember2019-12-310000764180us-gaap:NondesignatedMemberus-gaap:EquityContractMemberus-gaap:NetInvestmentHedgingMember2020-12-310000764180us-gaap:NondesignatedMemberus-gaap:EquityContractMemberus-gaap:NetInvestmentHedgingMember2019-12-310000764180us-gaap:NetInvestmentHedgingMember2020-12-310000764180us-gaap:NetInvestmentHedgingMember2019-12-310000764180mo:EquityContractPreemptiveRIghtsMember2020-01-012020-12-310000764180mo:EquityContractPreemptiveRIghtsMember2019-01-012019-12-310000764180mo:EquityContractWarrantMember2020-01-012020-12-310000764180mo:EquityContractWarrantMember2019-01-012019-12-310000764180mo:CronosGroupInc.Member2019-03-012019-03-310000764180us-gaap:NondesignatedMemberus-gaap:ForwardContractsMember2019-03-310000764180us-gaap:NondesignatedMemberus-gaap:ForwardContractsMember2019-01-012019-03-310000764180us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2020-01-012020-12-310000764180us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2019-01-012019-12-310000764180us-gaap:NetInvestmentHedgingMembermo:ForeignCurrencyDenominatedDebtMember2020-01-012020-12-310000764180us-gaap:NetInvestmentHedgingMembermo:ForeignCurrencyDenominatedDebtMember2019-01-012019-12-310000764180us-gaap:NetInvestmentHedgingMember2020-01-012020-12-310000764180us-gaap:NetInvestmentHedgingMember2019-01-012019-12-310000764180us-gaap:RevolvingCreditFacilityMembermo:RevolvingCreditFacilityDueAugust2023Memberus-gaap:LineOfCreditMember2020-01-012020-12-310000764180us-gaap:RevolvingCreditFacilityMembermo:RevolvingCreditFacilityDueAugust2023Memberus-gaap:LineOfCreditMember2020-12-31mo:Extension0000764180us-gaap:RevolvingCreditFacilityMembermo:RevolvingCreditFacilityDueAugust2023Memberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:LineOfCreditMember2020-01-012020-12-310000764180us-gaap:RevolvingCreditFacilityMembermo:RevolvingCreditFacilityDueAugust2023Memberus-gaap:LineOfCreditMember2020-03-012020-03-310000764180us-gaap:RevolvingCreditFacilityMembermo:RevolvingCreditFacilityDueAugust2023Memberus-gaap:LineOfCreditMember2019-12-310000764180us-gaap:NotesPayableOtherPayablesMembermo:TermLoanAgreementMember2018-12-310000764180mo:TermLoanAgreementJUULandCronosMember2019-02-012019-02-280000764180mo:TermLoanAgreementJUULandCronosMember2019-01-012019-12-310000764180srt:MinimumMembermo:NotesTwoPointThreeFiveZeroPercentToTenPointTwoZeroPercentDueThroughTwoThousandAndFortyFourMemberus-gaap:SeniorNotesMember2020-12-310000764180srt:MaximumMembermo:NotesTwoPointThreeFiveZeroPercentToTenPointTwoZeroPercentDueThroughTwoThousandAndFortyFourMemberus-gaap:SeniorNotesMember2020-12-310000764180mo:NotesTwoPointThreeFiveZeroPercentToTenPointTwoZeroPercentDueThroughTwoThousandAndFortyFourMemberus-gaap:SeniorNotesMember2020-12-310000764180mo:NotesTwoPointThreeFiveZeroPercentToTenPointTwoZeroPercentDueThroughTwoThousandAndFortyFourMemberus-gaap:SeniorNotesMember2019-12-310000764180us-gaap:LoansPayableMembermo:DebentureSevenPointSevenFivePercentDueTwoThousandAndTwentySevenMember2020-12-310000764180us-gaap:LoansPayableMembermo:DebentureSevenPointSevenFivePercentDueTwoThousandAndTwentySevenMember2019-12-310000764180srt:MinimumMembermo:NotesOnePercentToThreePointOneTwoFivePercentDueThroughTwoThousandAndThirtyOneMemberus-gaap:NotesPayableOtherPayablesMember2020-12-310000764180srt:MaximumMembermo:NotesOnePercentToThreePointOneTwoFivePercentDueThroughTwoThousandAndThirtyOneMemberus-gaap:NotesPayableOtherPayablesMember2020-12-310000764180mo:NotesOnePercentToThreePointOneTwoFivePercentDueThroughTwoThousandAndThirtyOneMemberus-gaap:NotesPayableOtherPayablesMember2020-12-310000764180mo:NotesOnePercentToThreePointOneTwoFivePercentDueThroughTwoThousandAndThirtyOneMemberus-gaap:NotesPayableOtherPayablesMember2019-12-310000764180mo:NotesTwoPointThreeFiveZeroPercentToTenPointTwoZeroPercentDueThroughTwoThousandAndFortyFourMemberus-gaap:SeniorNotesMembersrt:WeightedAverageMember2019-12-310000764180mo:NotesTwoPointThreeFiveZeroPercentToTenPointTwoZeroPercentDueThroughTwoThousandAndFortyFourMemberus-gaap:SeniorNotesMembersrt:WeightedAverageMember2020-12-310000764180mo:NotesOnePercentToThreePointOneTwoFivePercentDueThroughTwoThousandAndThirtyOneMemberus-gaap:NotesPayableOtherPayablesMembersrt:WeightedAverageMember2020-12-310000764180mo:NotesOnePercentToThreePointOneTwoFivePercentDueThroughTwoThousandAndThirtyOneMemberus-gaap:NotesPayableOtherPayablesMembersrt:WeightedAverageMember2019-12-310000764180mo:USDDenominatedNotesMemberus-gaap:SeniorNotesMember2020-05-310000764180mo:USDDenominatedNotesDueTwoThousandAndTwentyFiveMemberus-gaap:SeniorNotesMember2020-05-310000764180mo:USDDenominatedNotesDueTwoThousandAndThirtyMemberus-gaap:SeniorNotesMember2020-05-310000764180mo:USDDenominatedNotesDueTwoThousandandFiftyMemberus-gaap:SeniorNotesMember2020-05-310000764180us-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodOneMember2020-01-012020-12-310000764180us-gaap:SeniorNotesMember2020-01-012020-12-310000764180us-gaap:StockCompensationPlanMember2020-12-310000764180mo:SerialPreferredStockMember2020-12-3100007641802020-07-012020-09-3000007641802020-04-012020-06-300000764180mo:January2018ShareRepurchaseProgramMember2018-01-310000764180mo:January2018ShareRepurchaseProgramMember2018-05-310000764180mo:January2018ShareRepurchaseProgramMember2018-01-012019-06-300000764180mo:July2019ShareRepurchaseProgramMember2019-07-310000764180mo:July2019ShareRepurchaseProgramMember2020-04-300000764180mo:January2021ShareRepurchaseProgramMemberus-gaap:SubsequentEventMember2021-01-310000764180mo:July2019ShareRepurchaseProgramMember2019-01-012019-12-310000764180mo:January2018ShareRepurchaseProgramMember2019-01-012019-12-310000764180mo:January2018ShareRepurchaseProgramMember2018-01-012018-12-310000764180mo:July2015ShareRepurchaseProgramMember2018-01-012018-12-310000764180mo:July2015ShareRepurchaseProgramMember2015-07-310000764180mo:July2015ShareRepurchaseProgramMember2016-10-310000764180mo:July2015ShareRepurchaseProgramMember2017-07-310000764180mo:A2020PerformanceIncentivePlanMemberus-gaap:CommonStockMember2020-12-310000764180mo:A2015DirectorsPlanMemberus-gaap:CommonStockMember2020-12-310000764180us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310000764180us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-12-310000764180us-gaap:RestrictedStockUnitsRSUMember2018-01-012018-12-310000764180us-gaap:RestrictedStockUnitsRSUMember2020-12-310000764180us-gaap:RestrictedStockUnitsRSUMember2019-12-310000764180us-gaap:RestrictedStockUnitsRSUMember2018-12-310000764180mo:RestrictedStockAndRestrictedStockUnitsRSUsMember2020-01-012020-12-310000764180mo:RestrictedStockAndRestrictedStockUnitsRSUsMember2019-01-012019-12-310000764180mo:RestrictedStockAndRestrictedStockUnitsRSUsMember2018-01-012018-12-310000764180us-gaap:PerformanceSharesMember2020-01-012020-12-310000764180us-gaap:PerformanceSharesMember2019-01-012019-12-310000764180us-gaap:PerformanceSharesMember2018-01-012018-12-310000764180us-gaap:PerformanceSharesMember2020-12-310000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2017-12-310000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMembermo:ABInBevMember2017-12-310000764180us-gaap:AccumulatedTranslationAdjustmentMember2017-12-310000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-01-012018-12-310000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMembermo:ABInBevMember2018-01-012018-12-310000764180us-gaap:AccumulatedTranslationAdjustmentMember2018-01-012018-12-310000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-12-310000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMembermo:ABInBevMember2018-12-310000764180us-gaap:AccumulatedTranslationAdjustmentMember2018-12-310000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-01-012019-12-310000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMembermo:ABInBevMember2019-01-012019-12-310000764180us-gaap:AccumulatedTranslationAdjustmentMember2019-01-012019-12-310000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-310000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMembermo:ABInBevMember2019-12-310000764180us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-12-310000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMembermo:ABInBevMember2020-01-012020-12-310000764180us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-12-310000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMembermo:ABInBevMember2020-12-310000764180us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2020-01-012020-12-310000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2019-01-012019-12-310000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2018-01-012018-12-310000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2020-01-012020-12-310000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2019-01-012019-12-310000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2018-01-012018-12-310000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-12-310000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-01-012019-12-310000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-01-012018-12-310000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2018-01-012018-12-3100007641802017-01-012017-12-310000764180mo:AuditAdjustmentsPriorYearTaxAuditsMember2019-01-012019-12-310000764180mo:AccrualsnolongerrequiredMember2019-01-012019-12-310000764180us-gaap:EquityMethodInvestmentsMember2019-01-012019-12-310000764180us-gaap:StateAndLocalJurisdictionMember2020-12-310000764180mo:SmokeableProductsSegmentMember2020-01-012020-12-310000764180mo:SmokeableProductsSegmentMember2019-01-012019-12-310000764180mo:SmokeableProductsSegmentMember2018-01-012018-12-310000764180mo:OralTobaccoSegmentMember2020-01-012020-12-310000764180mo:OralTobaccoSegmentMember2019-01-012019-12-310000764180mo:OralTobaccoSegmentMember2018-01-012018-12-310000764180mo:WineSegmentMember2020-01-012020-12-310000764180mo:WineSegmentMember2018-01-012018-12-310000764180us-gaap:AllOtherSegmentsMember2020-01-012020-12-310000764180us-gaap:AllOtherSegmentsMember2019-01-012019-12-310000764180us-gaap:AllOtherSegmentsMember2018-01-012018-12-310000764180mo:CigarettesMembermo:SmokeableProductsSegmentMember2020-01-012020-12-310000764180mo:CigarettesMembermo:SmokeableProductsSegmentMember2019-01-012019-12-310000764180mo:CigarettesMembermo:SmokeableProductsSegmentMember2018-01-012018-12-310000764180mo:CigarsMembermo:SmokeableProductsSegmentMember2020-01-012020-12-310000764180mo:CigarsMembermo:SmokeableProductsSegmentMember2019-01-012019-12-310000764180mo:CigarsMembermo:SmokeableProductsSegmentMember2018-01-012018-12-310000764180us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembermo:McLaneCompanyIncMember2020-01-012020-12-310000764180us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembermo:McLaneCompanyIncMember2019-01-012019-12-310000764180us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembermo:McLaneCompanyIncMember2018-01-012018-12-310000764180us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembermo:CoreMarkHoldingCompanyInc.Member2020-01-012020-12-310000764180us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembermo:CoreMarkHoldingCompanyInc.Member2019-01-012019-12-310000764180us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembermo:CoreMarkHoldingCompanyInc.Member2018-01-012018-12-310000764180us-gaap:CustomerConcentrationRiskMembermo:TwoDistributorsMemberus-gaap:SalesRevenueNetMembermo:WineSegmentMember2020-01-012020-12-310000764180us-gaap:CustomerConcentrationRiskMembermo:TwoDistributorsMemberus-gaap:SalesRevenueNetMembermo:WineSegmentMember2019-01-012019-12-310000764180us-gaap:CustomerConcentrationRiskMembermo:TwoDistributorsMemberus-gaap:SalesRevenueNetMembermo:WineSegmentMember2018-01-012018-12-310000764180us-gaap:OperatingIncomeLossMembermo:PhilipMorrisUSAMembermo:NpmAdjustmentToCostOfSalesMembermo:NonParticipatingManufacturerArbitrationPanelDecisionMembermo:SmokeableProductsSegmentMember2020-01-012020-12-310000764180us-gaap:OperatingIncomeLossMembermo:PhilipMorrisUSAMembermo:NpmAdjustmentToCostOfSalesMembermo:NonParticipatingManufacturerArbitrationPanelDecisionMembermo:SmokeableProductsSegmentMember2018-01-012018-12-310000764180us-gaap:OperatingIncomeLossMembermo:PhilipMorrisUSAMembermo:NpmAdjustmentToCostOfSalesMembermo:NonParticipatingManufacturerArbitrationPanelDecisionMembermo:SmokeableProductsSegmentMember2019-01-012019-12-310000764180us-gaap:OperatingIncomeLossMembermo:PhilipMorrisUSAMembermo:TobaccoandHealthLitigationCasesMemberus-gaap:OperatingSegmentsMembermo:SmokeableProductsSegmentMember2020-01-012020-12-310000764180us-gaap:OperatingIncomeLossMembermo:PhilipMorrisUSAMembermo:TobaccoandHealthLitigationCasesMemberus-gaap:OperatingSegmentsMembermo:SmokeableProductsSegmentMember2019-01-012019-12-310000764180us-gaap:OperatingIncomeLossMembermo:PhilipMorrisUSAMembermo:TobaccoandHealthLitigationCasesMemberus-gaap:OperatingSegmentsMembermo:SmokeableProductsSegmentMember2018-01-012018-12-310000764180us-gaap:OperatingIncomeLossMembermo:TobaccoandHealthLitigationCasesMemberus-gaap:OperatingSegmentsMembermo:OralTobaccoSegmentMember2020-01-012020-12-310000764180us-gaap:OperatingIncomeLossMembermo:TobaccoandHealthLitigationCasesMemberus-gaap:OperatingSegmentsMembermo:OralTobaccoSegmentMember2019-01-012019-12-310000764180us-gaap:OperatingIncomeLossMembermo:TobaccoandHealthLitigationCasesMemberus-gaap:OperatingSegmentsMembermo:OralTobaccoSegmentMember2018-01-012018-12-310000764180mo:InterestAndOtherDebtExpenseNetMembermo:TobaccoandHealthLitigationCasesMemberus-gaap:MaterialReconcilingItemsMember2020-01-012020-12-310000764180mo:InterestAndOtherDebtExpenseNetMembermo:TobaccoandHealthLitigationCasesMemberus-gaap:MaterialReconcilingItemsMember2019-01-012019-12-310000764180mo:InterestAndOtherDebtExpenseNetMembermo:TobaccoandHealthLitigationCasesMemberus-gaap:MaterialReconcilingItemsMember2018-01-012018-12-310000764180mo:TobaccoandHealthLitigationCasesMember2020-01-012020-12-310000764180mo:TobaccoandHealthLitigationCasesMember2019-01-012019-12-310000764180mo:TobaccoandHealthLitigationCasesMember2018-01-012018-12-310000764180mo:COVID19Member2020-01-012020-12-310000764180mo:SmokeableProductsSegmentMembermo:COVID19Member2020-01-012020-12-310000764180mo:OralTobaccoSegmentMembermo:COVID19Member2020-01-012020-12-310000764180mo:PhilipMorrisCapitalCorporationMember2020-01-012020-12-310000764180mo:PhilipMorrisCapitalCorporationMember2019-01-012019-12-310000764180mo:PhilipMorrisCapitalCorporationMember2018-01-012018-12-310000764180us-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180us-gaap:PensionPlansDefinedBenefitMember2018-12-310000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-12-310000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2018-12-310000764180us-gaap:PensionPlansDefinedBenefitMember2020-01-012020-12-310000764180us-gaap:PensionPlansDefinedBenefitMember2019-01-012019-12-310000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-01-012020-12-310000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-01-012019-12-310000764180us-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000764180us-gaap:PensionPlansDefinedBenefitMember2018-01-012018-12-310000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2018-01-012018-12-310000764180us-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:FixedIncomeSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FixedIncomeSecuritiesMember2020-12-310000764180us-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2020-12-310000764180us-gaap:CorporateBondSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:CorporateBondSecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000764180mo:UsTreasuryAndForeignGovernmentSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermo:UsTreasuryAndForeignGovernmentSecuritiesMember2020-12-310000764180us-gaap:ExternalCreditRatingNonInvestmentGradeMemberus-gaap:FixedIncomeSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:ExternalCreditRatingNonInvestmentGradeMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:DefinedBenefitPlanEquitySecuritiesMembermo:EmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180mo:EmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:ExternalCreditRatingNonInvestmentGradeMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FixedIncomeSecuritiesMember2020-12-310000764180us-gaap:ExternalCreditRatingNonInvestmentGradeMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermo:EmergingMarketsMember2020-12-310000764180us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:USTreasuryAndGovernmentMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180us-gaap:USTreasuryAndGovernmentMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:MunicipalBondsMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180us-gaap:MunicipalBondsMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180us-gaap:FairValueInputsLevel1Membermo:CorporateDebtSecurityAboveInvestmentGradeMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:FairValueInputsLevel2Membermo:CorporateDebtSecurityAboveInvestmentGradeMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180mo:CorporateDebtSecurityAboveInvestmentGradeMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:FairValueInputsLevel1Membermo:CorporateDebtSecurityAboveInvestmentGradeMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180us-gaap:FairValueInputsLevel2Membermo:CorporateDebtSecurityAboveInvestmentGradeMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180mo:CorporateDebtSecurityAboveInvestmentGradeMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180mo:CorporateDebtSecurityBelowInvestmentGradeMemberus-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180mo:CorporateDebtSecurityBelowInvestmentGradeMemberus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180mo:CorporateDebtSecurityBelowInvestmentGradeMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180mo:CorporateDebtSecurityBelowInvestmentGradeMemberus-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180mo:CorporateDebtSecurityBelowInvestmentGradeMemberus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180mo:CorporateDebtSecurityBelowInvestmentGradeMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180us-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:DefinedBenefitPlanEquitySecuritiesUsMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180us-gaap:DefinedBenefitPlanEquitySecuritiesUsMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180mo:OtherInvestmentNetMemberus-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180mo:OtherInvestmentNetMemberus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180mo:OtherInvestmentNetMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180mo:OtherInvestmentNetMemberus-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180mo:OtherInvestmentNetMemberus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180mo:OtherInvestmentNetMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180mo:USLargeCapMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180mo:USLargeCapMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180mo:USSmallCapMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180mo:USSmallCapMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180mo:InternationalDevelopedMarketsMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180mo:InternationalDevelopedMarketsMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180us-gaap:OtherInvestmentsMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180us-gaap:OtherInvestmentsMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000764180us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000764180us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000764180us-gaap:USTreasuryAndGovernmentMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000764180us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-12-310000764180us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-12-310000764180us-gaap:USTreasuryAndGovernmentMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-12-310000764180us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2020-12-310000764180us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2020-12-310000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2020-12-310000764180us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2019-12-310000764180us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2019-12-310000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2019-12-310000764180us-gaap:FairValueInputsLevel1Membermo:CorporateDebtSecurityAboveInvestmentGradeMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000764180us-gaap:FairValueInputsLevel2Membermo:CorporateDebtSecurityAboveInvestmentGradeMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000764180mo:CorporateDebtSecurityAboveInvestmentGradeMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000764180us-gaap:FairValueInputsLevel1Membermo:CorporateDebtSecurityAboveInvestmentGradeMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-12-310000764180us-gaap:FairValueInputsLevel2Membermo:CorporateDebtSecurityAboveInvestmentGradeMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-12-310000764180mo:CorporateDebtSecurityAboveInvestmentGradeMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-12-310000764180mo:CorporateDebtSecurityBelowInvestmentGradeMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000764180mo:CorporateDebtSecurityBelowInvestmentGradeMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000764180mo:CorporateDebtSecurityBelowInvestmentGradeMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000764180mo:CorporateDebtSecurityBelowInvestmentGradeMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-12-310000764180mo:CorporateDebtSecurityBelowInvestmentGradeMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-12-310000764180mo:CorporateDebtSecurityBelowInvestmentGradeMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-12-310000764180mo:OtherInvestmentNetMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000764180mo:OtherInvestmentNetMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000764180mo:OtherInvestmentNetMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000764180mo:OtherInvestmentNetMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-12-310000764180mo:OtherInvestmentNetMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-12-310000764180mo:OtherInvestmentNetMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-12-310000764180us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000764180us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000764180us-gaap:FairValueInputsLevel12And3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000764180us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-12-310000764180us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-12-310000764180us-gaap:FairValueInputsLevel12And3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-12-310000764180mo:USLargeCapMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000764180mo:USLargeCapMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-12-310000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermo:InternationalDevelopedMarketsMember2020-12-310000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermo:InternationalDevelopedMarketsMember2019-12-310000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2020-12-310000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2019-12-310000764180us-gaap:OtherInvestmentsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000764180us-gaap:OtherInvestmentsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-12-310000764180us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-12-310000764180us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000764180srt:MaximumMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000764180srt:MaximumMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000764180us-gaap:PostemploymentRetirementBenefitsMember2020-12-310000764180us-gaap:PostemploymentRetirementBenefitsMember2019-12-310000764180us-gaap:PostemploymentRetirementBenefitsMember2020-01-012020-12-310000764180us-gaap:PostemploymentRetirementBenefitsMember2019-01-012019-12-310000764180us-gaap:PostemploymentRetirementBenefitsMember2018-01-012018-12-310000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:PensionPlansDefinedBenefitMember2018-01-012018-12-310000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-01-012018-12-310000764180us-gaap:PostemploymentRetirementBenefitsMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-01-012018-12-310000764180mo:AllowanceDiscountsMember2019-12-310000764180mo:AllowanceReturnedGoodsMember2019-12-310000764180mo:AllowanceDiscountsMember2018-12-310000764180mo:AllowanceReturnedGoodsMember2018-12-310000764180mo:AllowanceDiscountsMember2017-12-310000764180mo:AllowanceReturnedGoodsMember2017-12-310000764180mo:AllowanceDiscountsMember2020-01-012020-12-310000764180mo:AllowanceReturnedGoodsMember2020-01-012020-12-310000764180mo:AllowanceDiscountsMember2019-01-012019-12-310000764180mo:AllowanceReturnedGoodsMember2019-01-012019-12-310000764180mo:AllowanceDiscountsMember2018-01-012018-12-310000764180mo:AllowanceReturnedGoodsMember2018-01-012018-12-310000764180mo:AllowanceDiscountsMember2020-12-310000764180mo:AllowanceReturnedGoodsMember2020-12-310000764180us-gaap:AllowanceForLossesOnFinanceReceivablesMember2019-12-310000764180us-gaap:AllowanceForLossesOnFinanceReceivablesMember2018-12-310000764180us-gaap:AllowanceForLossesOnFinanceReceivablesMember2017-12-310000764180us-gaap:AllowanceForLossesOnFinanceReceivablesMember2020-01-012020-12-310000764180us-gaap:AllowanceForLossesOnFinanceReceivablesMember2019-01-012019-12-310000764180us-gaap:AllowanceForLossesOnFinanceReceivablesMember2018-01-012018-12-310000764180us-gaap:AllowanceForLossesOnFinanceReceivablesMember2020-12-31mo:statemo:claim0000764180mo:IndividualSmokingAndHealthCasesMember2020-12-310000764180mo:IndividualSmokingAndHealthCasesMember2019-12-310000764180mo:IndividualSmokingAndHealthCasesMember2018-12-310000764180mo:HealthCareCostRecoveryActionsMember2020-12-310000764180mo:HealthCareCostRecoveryActionsMember2019-12-310000764180mo:HealthCareCostRecoveryActionsMember2018-12-310000764180mo:EvaporLitigationMember2020-12-310000764180mo:EvaporLitigationMember2019-12-310000764180mo:EvaporLitigationMember2018-12-310000764180mo:OtherTabaccoRelatedCasesMember2020-12-310000764180mo:OtherTabaccoRelatedCasesMember2019-12-310000764180mo:OtherTabaccoRelatedCasesMember2018-12-310000764180us-gaap:PendingLitigationMembermo:IndividualSmokingAndHealthCasesMemberstpr:NM2020-12-31mo:case0000764180us-gaap:PendingLitigationMembermo:IndividualSmokingAndHealthCasesMemberstpr:MA2020-12-310000764180us-gaap:PendingLitigationMembermo:IndividualSmokingAndHealthCasesMemberstpr:FL2020-12-310000764180mo:ETSSmokingandHealthCaseFlightAttendantsMemberus-gaap:PendingLitigationMember2020-01-012020-12-310000764180mo:ETSSmokingandHealthCaseFlightAttendantsMemberus-gaap:PendingLitigationMember2018-03-012018-03-31mo:lawsuit0000764180country:CAmo:EvaporLitigationMember2020-12-310000764180mo:PendingIndividualLawsuitsMembermo:EvaporLitigationMember2020-12-310000764180mo:PendingLawsuitsFiledByStateOrLocalGovernmentsMembermo:EvaporLitigationMember2020-12-310000764180country:CAmo:HealthCareCostRecoveryActionsMemberus-gaap:SubsequentEventMember2021-01-250000764180mo:PhilipMorrisUSAMembercountry:CAmo:HealthCareCostRecoveryActionsMemberus-gaap:SubsequentEventMember2021-01-250000764180country:CAmo:HealthCareCostRecoveryActionsMemberus-gaap:SubsequentEventMembermo:PhilipMorrisUSAandAltriaGroupMember2021-01-250000764180country:CAus-gaap:SubsequentEventMembermo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMembermo:PhilipMorrisUSAandAltriaGroupMember2021-01-250000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesMemberus-gaap:SubsequentEventMember2021-01-250000764180mo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:NonEngleProgenyCasesMember1999-01-012021-01-250000764180mo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:NonEngleProgenyCasesMemberstpr:AK1999-01-012021-01-250000764180stpr:CAmo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:NonEngleProgenyCasesMember1999-01-012021-01-250000764180stpr:CTmo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:NonEngleProgenyCasesMember1999-01-012021-01-250000764180mo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:NonEngleProgenyCasesMemberstpr:FL1999-01-012021-01-250000764180stpr:LAmo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:NonEngleProgenyCasesMember1999-01-012021-01-250000764180mo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:NonEngleProgenyCasesMemberstpr:MA1999-01-012021-01-250000764180mo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:NonEngleProgenyCasesMemberstpr:MS1999-01-012021-01-250000764180mo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:NonEngleProgenyCasesMemberstpr:MO1999-01-012021-01-250000764180stpr:NHmo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:NonEngleProgenyCasesMember1999-01-012021-01-250000764180mo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:NonEngleProgenyCasesMemberstpr:NJ1999-01-012021-01-250000764180mo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:NonEngleProgenyCasesMemberstpr:NY1999-01-012021-01-250000764180mo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:NonEngleProgenyCasesMemberstpr:OH1999-01-012021-01-250000764180mo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:NonEngleProgenyCasesMemberstpr:PA1999-01-012021-01-250000764180mo:PhilipMorrisUSAMemberstpr:RIus-gaap:SubsequentEventMembermo:NonEngleProgenyCasesMember1999-01-012021-01-250000764180mo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:NonEngleProgenyCasesMemberstpr:TN1999-01-012021-01-250000764180mo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:NonEngleProgenyCasesMemberstpr:WV1999-01-012021-01-250000764180mo:TobaccoandHealthJudgmentMember2004-10-012020-12-310000764180mo:EngleProgenyCasesMember2004-10-012020-12-310000764180mo:TobaccoandHealthJudgmentMembermo:LitigationCasesResultsMember2020-01-012020-12-310000764180mo:TobaccoandHealthJudgmentMembermo:LitigationCasesResultsMember2019-01-012019-12-310000764180mo:TobaccoandHealthJudgmentMembermo:LitigationCasesResultsMember2018-01-012018-12-310000764180mo:InterestExpenseRelatedToLitigationMember2020-01-012020-12-310000764180mo:InterestExpenseRelatedToLitigationMember2019-01-012019-12-310000764180mo:InterestExpenseRelatedToLitigationMember2018-01-012018-12-310000764180mo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMemberus-gaap:AssetsMember2020-12-310000764180mo:NonEngleProgenySmokingAndHealthCasePrincipeMember2020-02-290000764180mo:NonEngleProgenySmokingandHealthCaseGreeneMember2019-09-300000764180mo:NonEngleProgenySmokingandHealthCaseGreeneMember2020-05-310000764180mo:NonEngleProgenySmokingandHealthCaseLaramieMember2019-08-310000764180mo:NonEngleProgenySmokingandHealthCaseGentileMember2017-10-310000764180mo:NonEngleProgenySmokingandHealthCaseGentileMembermo:PhilipMorrisUSAMember2017-10-310000764180mo:EngleProgenyCasesMember2000-07-310000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesMember2000-07-310000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesMember2006-07-012006-07-310000764180mo:EngleProgenyCasesStateMember2008-01-310000764180mo:EngleProgenyCasesStateMemberus-gaap:SubsequentEventMember2021-01-25mo:plantiff0000764180mo:EngleProgenyCasesStateMemberus-gaap:SubsequentEventMember2021-01-252021-01-250000764180mo:EngleProgenyCasesFederalMembermo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMember2021-01-250000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesMemberus-gaap:SubsequentEventMember2021-01-252021-01-250000764180mo:EngleProgenyCasesStateMembermo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMember2021-01-252021-01-250000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesPearsonDCohenCollarChaconMemberMemberus-gaap:SubsequentEventMember2021-01-252021-01-250000764180mo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:EngleProgenyCasesReiderandBanksMember2021-01-252021-01-250000764180mo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:EngleProgenyCasesWeingartandHancockMember2021-01-252021-01-250000764180mo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:EngleProgenyCasesPollariMember2021-01-252021-01-250000764180mo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:EngleProgenyCasesGlogerRintoulandDuignamMember2021-01-252021-01-250000764180mo:EngleProgenyCasesFreemanMembermo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMember2021-01-252021-01-250000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesBergerMember2014-09-300000764180mo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMembermo:EngleProgenyCasesBergerMember2014-09-300000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesBergerMember2018-10-012018-12-310000764180mo:EngleProgenyCasesSantoroMemberus-gaap:PendingLitigationMember2017-03-310000764180mo:EngleProgenyCasesSantoroMembermo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMember2017-03-310000764180mo:EngleProgenyCasesSantoroMemberus-gaap:PendingLitigationMember2020-04-012020-06-300000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesDuignanMember2020-02-290000764180mo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMembermo:EngleProgenyCasesDuignanMember2020-02-290000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesCuddiheeMember2020-01-310000764180mo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMembermo:EngleProgenyCasesCuddiheeMember2020-01-310000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesRintoulMember2019-11-300000764180mo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMembermo:EngleProgenyCasesRintoulMember2019-11-300000764180mo:EngleProgenyCasesGlogerMemberus-gaap:PendingLitigationMember2019-11-300000764180mo:EngleProgenyCasesGlogerMembermo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMember2019-11-300000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesMcCallMember2019-03-310000764180mo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMembermo:EngleProgenyCasesMcCallMember2019-03-310000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesNeffMember2019-03-310000764180mo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMembermo:EngleProgenyCasesNeffMember2019-03-310000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesMahfuzMember2019-02-280000764180mo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMembermo:EngleProgenyCasesMahfuzMember2019-02-280000764180mo:EngleProgenyCasesHollimanMemberus-gaap:PendingLitigationMember2019-02-280000764180mo:EngleProgenyCasesHollimanMembermo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMember2019-02-280000764180mo:EngleProgenyCasesChadwellMemberus-gaap:PendingLitigationMember2018-09-300000764180mo:EngleProgenyCasesChadwellMembermo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMember2018-09-300000764180mo:EngleProgenyCasesKaplanMemberus-gaap:PendingLitigationMember2018-07-310000764180mo:EngleProgenyCasesKaplanMembermo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMember2018-07-310000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesR.DouglasMember2017-11-300000764180mo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMembermo:EngleProgenyCasesR.DouglasMember2017-11-300000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesSommersMember2017-04-300000764180mo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMembermo:EngleProgenyCasesSommersMember2017-04-300000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesSommersMember2020-01-012020-12-310000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesCooperMember2015-09-300000764180mo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMembermo:EngleProgenyCasesCooperMember2015-09-300000764180mo:EngleProgenyCasesD.BrownMemberus-gaap:PendingLitigationMember2015-01-310000764180mo:EngleProgenyCasesD.BrownMembermo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMember2015-01-310000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesHarrisMember2014-07-310000764180mo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMembermo:EngleProgenyCasesHarrisMember2014-07-310000764180us-gaap:SettledLitigationMembermo:EngleProgenyCasesDeanMember2020-07-012020-09-300000764180us-gaap:SettledLitigationMembermo:EngleProgenyCasesLandiMember2020-04-012020-06-300000764180mo:EngleProgenyCasesTheisMemberus-gaap:SettledLitigationMember2020-01-012020-03-310000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesNaugleGoreM.BrownJordanMember2020-12-310000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesNaugleMember2020-01-012020-12-310000764180mo:EngleProgenyCasesGoreMembermo:PhilipMorrisUSAMember2020-01-012020-12-310000764180mo:EngleProgenyCasesM.BrownMembermo:PhilipMorrisUSAMember2020-01-012020-12-310000764180mo:EngleProgenyCasesJordanMembermo:PhilipMorrisUSAMember2020-01-012020-12-310000764180mo:PhilipMorrisUSAMember2020-04-012020-06-300000764180mo:PhilipMorrisUSAMember2020-01-012020-03-310000764180mo:EngleProgenyCasesStateMemberstpr:FL2009-06-300000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember1996-05-012020-12-310000764180mo:PhilipMorrisUSAMemberstpr:ARmo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember1996-05-012020-12-310000764180stpr:CAmo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember1996-05-012020-12-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMemberstpr:DE1996-05-012020-12-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMemberstpr:DC1996-05-012020-12-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMemberstpr:FL1996-05-012020-12-310000764180stpr:ILmo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember1996-05-012020-12-310000764180mo:PhilipMorrisUSAMemberstpr:IAmo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember1996-05-012020-12-310000764180stpr:KSmo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember1996-05-012020-12-310000764180stpr:LAmo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember1996-05-012020-12-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMemberstpr:MD1996-05-012020-12-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMemberstpr:MI1996-05-012020-12-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMemberstpr:MN1996-05-012020-12-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMemberstpr:NV1996-05-012020-12-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMemberstpr:NJ1996-05-012020-12-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMemberstpr:NY1996-05-012020-12-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMemberstpr:OH1996-05-012020-12-310000764180mo:PhilipMorrisUSAMemberstpr:OKmo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember1996-05-012020-12-310000764180mo:PhilipMorrisUSAMemberstpr:ORmo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember1996-05-012020-12-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMemberstpr:PA1996-05-012020-12-310000764180country:PRmo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember1996-05-012020-12-310000764180stpr:SCmo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember1996-05-012020-12-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMemberstpr:TX1996-05-012020-12-310000764180mo:PhilipMorrisUSAMemberstpr:WImo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember1996-05-012020-12-310000764180us-gaap:SubsequentEventMembermo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMembermo:PhilipMorrisUSAandAltriaGroupMembermo:BritishColumbiaSaskatchewanMember2021-01-25mo:manufacture0000764180mo:CanadianTobaccoManufacturersMembercountry:CAmo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember2019-03-31mo:ruling0000764180mo:CanadianTobaccoManufacturersMembercountry:CAmo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember2019-03-012019-03-310000764180country:CAmo:HealthCareCostRecoveryActionsMemberus-gaap:ThreatenedLitigationMember2020-12-310000764180mo:CanadianTobaccoManufacturersMembercountry:CAmo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember2020-12-310000764180mo:HealthCareCostRecoveryActionsMember1998-11-011998-11-300000764180mo:HealthCareCostRecoveryActionsMember1998-11-300000764180mo:HealthCareCostRecoveryActionsMember2020-01-012020-12-310000764180mo:HealthCareCostRecoveryActionsMember2019-01-012019-12-310000764180mo:HealthCareCostRecoveryActionsMember2018-01-012018-12-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActionsMemberus-gaap:SettledLitigationMember2020-01-012020-12-310000764180mo:HealthCareCostRecoveryActions20032015NPMAdjustmentsMembermo:PhilipMorrisUSAMemberus-gaap:SettledLitigationMember2017-10-012017-10-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions20042017Memberus-gaap:SettledLitigationMember2017-10-012017-10-31mo:settlement_development0000764180mo:HealthCareCostRecoveryActions20032015NPMAdjustmentsMembermo:PhilipMorrisUSAMemberus-gaap:SettledLitigationMember2017-12-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions20042017Memberus-gaap:SettledLitigationMember2020-01-012020-12-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions20042017Memberus-gaap:SettledLitigationMember2018-04-012018-04-300000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions20042017Memberus-gaap:SettledLitigationMember2019-04-012019-04-300000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions20042017Memberus-gaap:SettledLitigationMember2020-04-012020-04-300000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActionsMember2017-01-012017-12-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActionsMember2018-01-012018-12-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActionsMember2019-01-012019-03-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions20042017Memberus-gaap:SettledLitigationMember2020-07-012020-09-300000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActionsMember2020-07-012020-09-300000764180mo:PhilipMorrisUSAMemberus-gaap:SettledLitigationMemberstpr:NYmo:HealthCareCostRecoveryActionsTransitionYears20042017Member2020-01-012020-12-310000764180mo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMembermo:HealthCareCostRecoveryActions2003NPMAdjustmentMember2013-09-012013-09-300000764180mo:PhilipMorrisUSAMemberus-gaap:SettledLitigationMembermo:HealthCareCostRecoveryActions2003NPMAdjustmentMember2013-09-012013-09-300000764180mo:MarylandMissouriNewMexicoandPennsylvaniaMembermo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMembermo:HealthCareCostRecoveryActions2003NPMAdjustmentMember2013-09-012013-09-300000764180us-gaap:CostOfSalesMembermo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMembermo:HealthCareCostRecoveryActions2003NPMAdjustmentMember2013-09-012013-09-300000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2004NPMAdjustmentMember2020-04-012020-04-300000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2004NPMAdjustmentMember2020-10-012020-12-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2004NPMAdjustmentMember2020-01-012020-12-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2005NPMAdjustmentMember2020-01-012020-12-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2006NPMAdjustmentMember2020-01-012020-12-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2007NPMAdjustmentMember2020-01-012020-12-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2008NPMAdjustmentMember2020-01-012020-12-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2009NPMAdjustmentMember2020-01-012020-12-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2010NPMAdjustmentMember2020-01-012020-12-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2011NPMAdjustmentMember2020-01-012020-12-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2012NPMAdjustmentMember2020-01-012020-12-310000764180mo:HealthCareCostRecoveryActions2013NPMAdjustmentMembermo:PhilipMorrisUSAMember2020-01-012020-12-310000764180mo:HealthCareCostRecoveryActions2014NPMAdjustmentMembermo:PhilipMorrisUSAMember2020-01-012020-12-310000764180mo:HealthCareCostRecoveryActions2015NPMAdjustmentsMembermo:PhilipMorrisUSAMember2020-01-012020-12-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember2020-01-012020-12-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2017NPMAdjustmentsMember2020-01-012020-12-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2018NPMAdjustmentsMember2020-01-012020-12-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2019NPMAdjustmentsMember2020-01-012020-12-310000764180mo:OtherDisputesUndertheStateSettlementAgreementsMembermo:PhilipMorrisUSAMember2018-08-012018-08-310000764180mo:OtherDisputesUndertheStateSettlementAgreementsMembermo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMember2021-01-012021-01-310000764180mo:FederalGovernmentsLawsuitMember2006-08-012006-08-310000764180mo:ImplementationofCorrectiveCommunicationsMembermo:FederalGovernmentsLawsuitMember2014-01-012019-12-310000764180mo:PendingClassActionLawsuitsMemberus-gaap:SubsequentEventMembermo:EvaporLitigationMember2021-01-250000764180us-gaap:SubsequentEventMembermo:PendingIndividualLawsuitsMembermo:EvaporLitigationMember2021-01-250000764180mo:PendingLawsuitFiledBySchoolDistrictMemberus-gaap:SubsequentEventMembermo:EvaporLitigationMember2021-01-250000764180us-gaap:SubsequentEventMembermo:EvaporLitigationMember2021-01-250000764180mo:JUULMember2020-04-30mo:shareholder0000764180us-gaap:SubsequentEventMember2021-01-252021-01-2500007641802019-10-012019-12-3100007641802020-08-012020-08-310000764180mo:LightsMemberus-gaap:SubsequentEventMember2021-01-25mo:court0000764180us-gaap:SubsequentEventMembermo:LightsUltraLightsClassActionsMember2021-01-250000764180mo:USTLitigationMemberus-gaap:SubsequentEventMembermo:PendingIndividualLawsuitsMember2021-01-250000764180us-gaap:LetterOfCreditMember2020-12-310000764180mo:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2020-12-310000764180mo:LightsMembermo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMember2021-01-2500007641802020-09-012020-09-3000007641802020-10-012020-10-310000764180us-gaap:SubsequentEventMember2021-01-012021-01-3100007641802020-01-012020-03-3100007641802020-10-012020-12-3100007641802019-01-012019-03-3100007641802019-04-012019-06-3000007641802019-07-012019-09-300000764180mo:JUULMember2020-01-012020-03-310000764180mo:JUULMember2020-04-012020-06-300000764180mo:JUULMember2020-07-012020-09-300000764180mo:ABInBevMember2020-01-012020-03-310000764180mo:ABInBevMember2020-04-012020-06-300000764180mo:ABInBevMember2020-07-012020-09-300000764180mo:ABInBevMember2020-10-012020-12-310000764180mo:CronosGroupInc.Member2020-01-012020-03-310000764180mo:CronosGroupInc.Member2020-04-012020-06-300000764180mo:CronosGroupInc.Member2020-07-012020-09-300000764180mo:CronosGroupInc.Member2020-10-012020-12-310000764180mo:COVID19Member2020-01-012020-03-310000764180mo:COVID19Member2020-04-012020-06-300000764180mo:COVID19Member2020-07-012020-09-300000764180mo:COVID19Member2020-10-012020-12-310000764180mo:ABInBevMember2019-01-012019-03-310000764180mo:ABInBevMember2019-04-012019-06-300000764180mo:ABInBevMember2019-07-012019-09-300000764180mo:ABInBevMember2019-10-012019-12-310000764180mo:CronosGroupInc.Member2019-01-012019-03-310000764180mo:CronosGroupInc.Member2019-04-012019-06-300000764180mo:CronosGroupInc.Member2019-07-012019-09-300000764180mo:CronosGroupInc.Member2019-10-012019-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
    ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2020
OR
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                     to                     
Commission File Number 1-08940

ALTRIA GROUP, INC.
(Exact name of registrant as specified in its charter)
Virginia13-3260245
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
6601 West Broad Street, Richmond,Virginia23230
(Address of principal executive offices)(Zip Code)

804-274-2200
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading SymbolsName of each exchange on which registered
Common Stock, $0.33  1/3 par valueMONew York Stock Exchange
1.000% Notes due 2023
MO23ANew York Stock Exchange
1.700% Notes due 2025
MO25New York Stock Exchange
2.200% Notes due 2027
MO27New York Stock Exchange
3.125% Notes due 2031
MO31New York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. þ Yes ¨ No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. ¨ Yes þ No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days þ Yes ¨ No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files) þ Yes ¨ No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerþAccelerated filer
Non-accelerated filer Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes þ No
As of June 30, 2020, the aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was approximately $73 billion based on the closing sale price of the common stock as reported on the New York Stock Exchange.
Class                           Outstanding at February 15, 2021
Common Stock, $0.33  1/3 par value
1,858,689,654 shares



DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive proxy statement for use in connection with its annual meeting of shareholders to be held on May 20, 2021, to be filed with the Securities and Exchange Commission on or about April 8, 2021, are incorporated by reference into Part III hereof.






TABLE OF CONTENTS
  Page
PART I  
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.
PART II 
Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
PART III 
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
PART IV 
Item 15.
Item 16.
 




Table of Contents
Part I
Item 1. Business.
General Development of Business
When used in this Annual Report on Form 10-K (“Form 10-K”), the terms “Altria,” “we,” “us” and “our” refers to Altria Group, Inc. and its subsidiaries, unless the context requires otherwise.
Altria’s 10-Year Vision is to responsibly lead the transition of adult smokers to a non-combustible future (“Vision”). Altria is Moving Beyond Smoking, leading the way in moving adult smokers away from cigarettes by taking action to transition millions to potentially less harmful choices - believing it is a substantial opportunity for adult tobacco consumers, Altria’s businesses and society.
At December 31, 2020, Altria’s wholly owned subsidiaries included Philip Morris USA Inc. (“PM USA”), which is engaged in the manufacture and sale of cigarettes in the United States (including super premium cigarettes previously manufactured and sold by Sherman Group Holdings, LLC and its subsidiaries (“Nat Sherman”)); John Middleton Co. (“Middleton”), which is engaged in the manufacture and sale of machine-made large cigars and pipe tobacco and is a wholly owned subsidiary of PM USA; UST LLC (“UST”), which through its wholly owned subsidiaries, including U.S. Smokeless Tobacco Company LLC (“USSTC”) and Ste. Michelle Wine Estates Ltd. (“Ste. Michelle”), is engaged in the manufacture and sale of moist smokeless tobacco products (“MST”), snus products and wine; and Philip Morris Capital Corporation (“PMCC”), which maintains a portfolio of finance assets, substantially all of which are leveraged leases. In addition, at December 31, 2020, Altria owned an 80% interest in Helix Innovations LLC (“Helix”), which is engaged in the manufacture and sale of oral nicotine pouches. Other Altria wholly owned subsidiaries included Altria Group Distribution Company, which provides sales and distribution services to certain Altria operating subsidiaries, and Altria Client Services LLC (“ALCS”), which provides various support services in areas such as legal, regulatory, consumer engagement, finance, human resources and external affairs to Altria and its subsidiaries.
In 2019, Helix acquired Burger Söhne Holding and its subsidiaries as well as certain affiliated companies (the “Burger Group”) that are engaged in the manufacture and sale of on! oral nicotine pouches. At closing, Altria owned an 80% interest in Helix, for which Altria paid $353 million in 2019.
In the first quarter of 2020, Altria renamed its smokeless products segment as the oral tobacco products segment. Altria’s reportable segments are smokeable products, oral tobacco products and wine. The financial services and the innovative tobacco products businesses are included in an all other category due to the continued reduction of the lease portfolio of PMCC and the relative financial contribution of Altria’s innovative tobacco products businesses to Altria’s consolidated results. For further information, see Note 15. Segment Reporting to the consolidated financial statements in Item 8. Financial Statements and Supplementary Data of this Form 10-K (“Item 8”).
At December 31, 2020, Altria’s investments in equity securities consisted of Anheuser-Busch InBev SA/NV (“ABI”), Cronos Group Inc. (“Cronos”) and JUUL Labs, Inc. (“JUUL”). Altria accounts for its investments in ABI and Cronos under the equity method of accounting using a one-quarter lag. Altria accounts for its equity investment in JUUL under the fair value option.
At December 31, 2020, Altria had a 10.0% ownership interest in ABI.
In December 2018, Altria made an investment in JUUL by purchasing shares of non-voting convertible common stock of JUUL representing a 35% ownership interest. JUUL is engaged in the manufacture and sale of e-vapor products in the U.S. and certain international markets. In November 2020, Altria exercised its rights to convert its non-voting shares to voting shares (“Share Conversion”). Altria does not currently intend to exercise its additional governance rights obtained upon Share Conversion, including the right to elect directors to JUUL’s board, or to vote its JUUL shares other than as a passive investor, pending the outcome of the U.S. Federal Trade Commission (“FTC”) administrative complaint. At December 31, 2020, Altria had a 35% ownership interest in JUUL.
In March 2019, Altria acquired a 45% ownership interest in Cronos, a global cannabinoid company headquartered in Toronto, Canada. At December 31, 2020, Altria had a 43.5% ownership interest in Cronos.
For further discussion of Altria’s investments in equity securities, see Note 6. Investments in Equity Securities to the consolidated financial statements in Item 8 (“Note 6”).
Description of Business
Portions of the information relating to this Item are included in Operating Results by Business Segment in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations of this Form 10-K (“Item 7”).
Tobacco Space
Altria’s tobacco operating companies include PM USA, USSTC and other subsidiaries of UST, Middleton and Helix. Altria Group Distribution Company provides sales and distribution services to Altria’s tobacco operating companies.
The products of Altria’s tobacco subsidiaries include (i) smokeable tobacco products, consisting of combustible cigarettes manufactured and sold by PM USA (including super premium cigarettes previously manufactured and sold by Nat Sherman) and machine-made large

1

Table of Contents
cigars and pipe tobacco manufactured and sold by Middleton; and (ii) oral tobacco products, consisting of MST and snus products manufactured and sold by USSTC and oral nicotine pouches manufactured and sold by Helix.
Cigarettes: PM USA is the largest cigarette company in the United States. Marlboro, the principal cigarette brand of PM USA, has been the largest-selling cigarette brand in the United States for over 45 years. Total smokeable products segment’s cigarettes shipment volume in the United States was 101.4 billion units in 2020, a decrease of 0.4% from 2019.
Cigars: Middleton is engaged in the manufacture and sale of machine-made large cigars and pipe tobacco. Middleton contracts with a third-party importer to supply a majority of its cigars and sells substantially all of its cigars to customers in the United States. Black & Mild is the principal cigar brand of Middleton. Total smokeable products segment’s cigars shipment volume was approximately 1.8 billion units in 2020, an increase of 9.0% from 2019.
Oral tobacco products: USSTC is the leading producer and marketer of MST products. The oral tobacco products segment includes the premium brands, Copenhagen and Skoal, and value brands, Red Seal and Husky, sold by USSTC. In addition, the oral tobacco products segment includes on! oral nicotine pouches sold by Helix. Substantially all of the oral tobacco products are manufactured and sold to customers in the United States. Total oral tobacco products segment’s shipment volume was 819.6 million units in 2020, an increase of 1.2% from 2019, primarily driven by on!. The oral tobacco products category volume increased in 2020 driven primarily by growth in oral nicotine pouches.
Innovative tobacco products: In December 2013, Altria’s subsidiaries entered into a series of agreements with Philip Morris International Inc. (“PMI”), including an agreement that grants Altria an exclusive right to commercialize certain of PMI’s heated tobacco products in the United States, subject to the United States Food and Drug Administration’s (“FDA”) authorization of the applicable products. PMI submitted a pre-market tobacco product application (“PMTA”) and modified risk tobacco product application with the FDA for its electronically heated tobacco products, comprising the IQOS Tobacco Heating System. In April 2019, the FDA authorized the PMTA for the IQOS Tobacco Heating System and in July 2020, the FDA authorized the marketing of this system as a modified risk tobacco product with a reduced exposure claim. In December 2020, the FDA authorized the PMTA for a new generation of the IQOS Tobacco Heating System, IQOS 3. The modified risk tobacco product application for the original IQOS Tobacco Heating System does not apply to IQOS 3. Future generations of the IQOS Tobacco Heating System will require separate PMTA and modified risk tobacco production application authorization from the FDA.
Distribution, Competition and Raw Materials: Altria’s tobacco subsidiaries sell their tobacco products principally to wholesalers (including distributors) and large retail organizations, including chain stores.
The market for tobacco products is highly competitive, characterized by brand recognition and loyalty, with product quality, taste, price, product innovation, marketing, packaging and distribution constituting the significant methods of competition. Promotional activities include, in certain instances and where permitted by law, allowances, the distribution of incentive items, price promotions, product promotions, coupons and other discounts.
The Family Smoking Prevention and Tobacco Control Act (“FSPTCA”) provides the FDA with broad authority to regulate the design, manufacture, packaging, advertising, promotion, sale and distribution of tobacco products; the authority to require disclosures of related information; and the authority to enforce the FSPTCA and related regulations.
In the United States, under a contract growing program, PM USA purchases the majority of its burley and flue-cured leaf tobaccos directly from domestic tobacco growers. Under the terms of this program, PM USA agrees to purchase the amount of tobacco specified in the grower contracts that meets PM USA’s grade and quality standards. PM USA also purchases a portion of its tobacco requirements through leaf merchants.
USSTC purchases dark fire-cured, dark air-cured and burley leaf tobaccos from domestic tobacco growers under a contract growing program. Under the terms of this program, USSTC agrees to purchase the amount of tobacco specified in the grower contracts that meets USSTC’s grade and quality standard.
Middleton purchases burley, dark air-cured and flue-cured leaf tobaccos through leaf merchants. Middleton does not have a contract growing program.
Altria’s tobacco subsidiaries believe there is an adequate supply of tobacco in the world markets to satisfy their current and anticipated production requirements.
For further discussion of the foregoing matters, the tobacco business environment, trends in market demand and competitive conditions, and related risks, see Item 1A. Risk Factors of this Form 10-K (“Item 1A”) and Tobacco Space - Business Environment in Item 7.
Wine
Ste. Michelle is a producer and supplier of premium varietal and blended table wines and of sparkling wines. Ste. Michelle is a leading producer of Washington state wines, primarily Chateau Ste. Michelle and 14 Hands, and owns wineries in or distributes wines from several other domestic and foreign wine regions. Ste. Michelle’s total 2020 wine shipment volume of approximately 7.3 million cases decreased 12.0% from 2019.

2

Table of Contents
Ste. Michelle holds an 85% ownership interest in Michelle-Antinori, LLC, which owns Stag’s Leap Wine Cellars in Napa Valley. Ste. Michelle also owns Conn Creek in Napa Valley, Patz & Hall in Sonoma and Erath in Oregon. In addition, Ste. Michelle imports and markets Antinori wine and Champagne Nicolas Feuillatte products in the United States.
Distribution, Competition and Raw Materials: Key elements of Ste. Michelle’s strategy are expanded domestic distribution of its wines, especially in certain retail channels categories such as restaurants, wholesale clubs, supermarkets, wine shops and mass merchandisers, and a focus on improving product mix to higher-priced, premium products.
Ste. Michelle uses grapes harvested from its own vineyards or purchased from independent growers, as well as bulk wine purchased from other sources. At the present time, Ste. Michelle believes there is a sufficient supply of grapes and bulk wine available in the market to satisfy its current and expected production requirements.
For further discussion of the foregoing matters, the wine business environment, trends in market demand and competitive conditions, and related risks, see Item 1A and Wine Segment - Business Environment in Item 7.
Financial Services Business
In 2003, PMCC ceased making new investments and began focusing exclusively on managing its portfolio of finance assets in order to maximize its operating results and cash flows from its existing lease portfolio activities and asset sales. Altria expects to complete the wind-down of this business by the end of 2022.
Other Matters
Customers: For a discussion of PM USA, USSTC, Helix and Middleton’s largest customers, including their percentages of Altria’s consolidated net revenues for the years ended December 31, 2020, 2019 and 2018, see Note 15. Segment Reporting to the consolidated financial statements in Item 8 (“Note 15”).
Executive Officers of Altria: The disclosure regarding executive officers is included in Item 10. Directors, Executive Officers and Corporate Governance - Information about Our Executive Officers as of February 15, 2021 of this Form 10-K.
Human Capital Resources: We believe our workforce is critical to achieving our Vision. Attracting, developing and retaining the best talent with the skills to make significant progress against our Vision is a key business priority. Moreover, we recognize the importance of doing business the right way. We believe culture influences employee actions and decision-making. This is why we dedicate resources to promoting a vibrant, inclusive workplace; attracting, developing and retaining talented, diverse employees; promoting a culture of compliance and integrity; creating a safe workplace; and rewarding and recognizing employees for both the results they deliver and, importantly, how they deliver them.
Oversight and Management
Our Human Resources department is responsible for managing employment-related matters, including recruiting and hiring, onboarding, compensation design and implementation, performance management, advancement and succession planning and professional and learning development. Our inclusion and diversity (“I&D”) programs are managed by our Corporate Citizenship department. Our Board of Directors (“Board of Directors” or “Board”) and two of our Board’s committees provide oversight of human capital matters. The Compensation and Talent Development Committee reviews initiatives and programs related to corporate culture and enterprise-wide talent development, including our I&D initiatives. The Nominating, Corporate Governance and Social Responsibility Committee reviews our social responsibility initiatives and goals, which include our efforts to work with diverse, high-quality suppliers and to address societal issues within our companies’ supply chains.
Inclusion and Diversity
We recognize the critical importance of I&D in pursuing our Vision and believe in the value of a workforce composed of a broad spectrum of backgrounds and cultures. In 2020, we established the following aspirational I&D aiming points to help guide our efforts over the next 10 years:
Be an inclusive place to work for all employees, regardless of level, demographic group or work function.
Have equal numbers of men and women among our vice president and director-level employees.
Increase our vice president and director-level employees who are Asian, Black, Hispanic or two or more races to at least 30%.
Increase our vice president and director-level employees who are LGBTQ+, a person with a disability or a veteran.
Have diverse functional leadership teams that reflect the organizations they lead.
We also believe in the importance of diverse suppliers throughout our companies’ supply chains, including minority, women, veteran and LGBTQ+-owned businesses.
Compensation and Benefits
Our compensation and benefits programs are designed to help us attract, retain and motivate strong talent. However, we recognize that the decreasing social acceptance of tobacco usage may impact our ability to attract and retain talent. We work to manage this risk by, among other things, targeting total compensation packages to be above peer companies for which we compete for talent. Depending on

3

Table of Contents
employee level, total compensation includes different elements – base salary, annual cash incentives, long-term equity and cash incentives and benefits. Our goal is to provide total compensation packages between the 50th and 75th percentiles of total compensation packages paid to employees in comparable positions at our peer companies upon attainment of business and individual goals.
We are committed to pay equity across our companies. Based on the most recent annual analysis we conducted in November 2020, for employees performing the same or similar duties, salaries of our female employees were 98.2% of those of our male employees, and salaries of our non-white employees were 98.5% of those of our white employees. After adjusting for factors generally considered to be legitimate differentiators of salary, such as performance and tenure, the percentages increased to 99.4% and 99.6%, respectively.
In addition to cash and equity compensation, we offer generous employee benefits such as significant company contributions to deferred profit sharing plans, consumer-driven health plan coverage, vacation and holiday pay, up to 12 weeks paid parental and family leave for birth, adoption and foster placement, and disability and life insurance. Our benefits also include wellness benefits and family creation assistance benefits, such as adoption assistance and coverage for fertility treatments. In response to the COVID-19 pandemic, for 2020 and 2021, we expanded dependent care coverage to include $5,000 employee reimbursement for remote learning and other dependent care costs. While there is some variability in employee benefits across our companies, the examples we provide are available to most employees.
We are also committed to investing in the educational development of our workforce through an unlimited tuition refund program for job-related courses or company-related degrees.
Attracting, Developing and Retaining Talent
Our salaried entry-level recruitment efforts focus on recruiting relationships with universities, internship opportunities and partnerships with organizations that support diverse students. We complement these recruiting efforts with hiring experienced employees with demonstrated leadership capabilities.
To help our employees succeed in their roles and develop in their careers, we emphasize ongoing training and leadership development opportunities. Building skills that drive innovation and aligning our employees to our Vision is important for our long-term success. The Human Resources department leads our learning and development efforts partnering with learning professionals embedded in functions throughout our operating and services companies. Employees have access to a wide variety of development programs, including new employee onboarding, classroom and self-guided training programs, technical training and our educational refund program for continuing education.
We regularly conduct anonymous employee engagement surveys to seek feedback on a variety of topics, including employee satisfaction, confidence in company leadership, corporate culture and culture of compliance. In addition, in 2020, we conducted employee surveys to gauge employee well-being in light of the COVID-19 pandemic and altered work environments, including working from home. Survey results, including comparisons to prior results, are shared with our employees and our Board and are used to modify or enhance our human capital management programs.
Workplace Safety
Our safety goal is for all employees to have an injury-free career. We regularly update our policies, procedures and equipment as new developments occur in safety and health standards and communicate safety messages and provide safety training as appropriate throughout our companies. Our most recent OSHA recordable injury rate of 1.9% from 2019 is lower than the benchmark for companies in the U.S. Beverage and Tobacco Product Manufacturing industry classification.
In response to the COVID-19 pandemic, we rapidly implemented safety measures to help protect our employees, including remote work for non-manufacturing salaried employees and, at our manufacturing locations, social distancing protocols, daily temperature checks and additional cleaning and sanitation practices.
Number of Employees and Labor Relations
At December 31, 2020, we employed approximately 7,100 people. Twenty-seven percent of those employees were hourly manufacturing employees and members of labor unions subject to collective bargaining agreements. We believe we engage and collaborate effectively with our hourly employees, as demonstrated by the positive working relationship between our companies and the unions. We also have long-term agreements that resolve any collective bargaining dispute through binding arbitration, which further demonstrates the trust-based relationship with the unions.
Supply Chain Human Capital Matters
In addition to supplier diversity efforts referenced above, we support efforts to address human capital concerns in the tobacco supply chain. For example, in our domestic tobacco supply chain, we use on-farm good agricultural practices assessments to assess growers’ compliance with practices related to labor management. Our tobacco companies also establish contract terms and conditions with tobacco growers addressing child and forced labor and conduct social compliance audits in high-risk tobacco growing regions.
More information about efforts discussed in this section can be found in our Corporate Responsibility Progress Report at www.altria.com/responsibility.

4

Table of Contents
Intellectual Property: Trademarks are of material importance to Altria and its operating companies, and are protected by registration or otherwise. In addition, as of December 31, 2020, the portfolio of United States patents owned by Altria’s businesses, as a whole, was material to Altria and its tobacco businesses. However, no one patent or group of related patents was material to Altria’s business or its tobacco businesses as of December 31, 2020. Altria’s businesses also have proprietary trade secrets, technology, know-how, processes and other intellectual property rights that are protected by appropriate confidentiality measures. Certain trade secrets are material to Altria and its tobacco and wine businesses.
Government Regulations: Altria and its subsidiaries are subject to various federal, state and local laws and regulations. For discussion of laws and regulations impacting Altria’s tobacco operating companies, see Tobacco Space - Business Environment in Item 7. For discussion of laws and regulations impacting the wine segment, see Wine Segment - Business Environment in Item 7.
Altria and its subsidiaries (and former subsidiaries) are also subject to various federal, state and local laws and regulations concerning the discharge of materials into the environment, or otherwise related to environmental protection, including, in the United States: The Clean Air Act, the Clean Water Act, the Resource Conservation and Recovery Act and the Comprehensive Environmental Response, Compensation and Liability Act (commonly known as “Superfund”), which can impose joint and several liability on each responsible party. Subsidiaries (and former subsidiaries) of Altria are involved in several matters subjecting them to potential costs of remediation and natural resource damages under Superfund or other laws and regulations. Altria’s subsidiaries expect to continue to make capital and other expenditures in connection with environmental laws and regulations. As discussed in Note 2. Summary of Significant Accounting Policies to the consolidated financial statements in Item 8 (“Note 2”), Altria provides for expenses associated with environmental remediation obligations on an undiscounted basis when such amounts are probable and can be reasonably estimated. Such accruals are adjusted as new information develops or circumstances change. Other than those amounts, it is not possible to reasonably estimate the cost of any environmental remediation and compliance efforts that subsidiaries of Altria may undertake in the future. In the opinion of management, however, compliance with environmental laws and regulations, including the payment of any remediation costs or damages and the making of related expenditures, has not had, and is not expected to have, a material adverse effect on Altria’s consolidated results of operations, capital expenditures, financial position or cash flows.
Available Information
Altria is required to file annual, quarterly and current reports, proxy statements and other information with the Securities and Exchange Commission (“SEC”).
Altria makes available free of charge on or through its website (www.altria.com) its Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as soon as reasonably practicable after Altria electronically files such material with, or furnishes it to, the SEC. Investors can access Altria’s filings with the SEC by visiting www.altria.com/secfilings.
The information on the respective websites of Altria and its subsidiaries is not, and shall not be deemed to be, a part of this Form 10-K or incorporated into any other filings Altria makes with the SEC.

Item 1A. Risk Factors.
The following risk factors should be read carefully in connection with evaluating our business and the forward-looking statements contained in this Form 10-K. Any of the following risks could materially adversely affect our business, our results of operations, our cash flows, our financial position and the actual outcome of matters as to which forward-looking statements are made in this Form 10-K.
We may from time to time make written or oral forward-looking statements, including earnings guidance and other statements contained in filings with the SEC, reports to security holders, press releases and investor webcasts. You can identify these forward-looking statements by use of words such as “strategy,” “expects,” “continues,” “plans,” “anticipates,” “believes,” “will,” “estimates,” “forecasts,” “intends,” “projects,” “goals,” “objectives,” “guidance,” “targets” and other words of similar meaning. You can also identify them by the fact that they do not relate strictly to historical or current facts.
We cannot guarantee that any forward-looking statement will be realized, although we believe we have been prudent in our plans, estimates and assumptions. Achievement of future results is subject to risks, uncertainties and assumptions that may prove to be inaccurate. Should known or unknown risks or uncertainties materialize, or should underlying estimates or assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated or projected. You should bear this in mind as you consider forward-looking statements and whether to invest in or remain invested in Altria’s securities. In connection with the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, we are identifying important factors that, individually or in the aggregate, could cause actual results and outcomes to differ materially from those contained in, or implied by, any forward-looking statements made by us; any such statement is qualified by reference to the following cautionary statements. We elaborate on these and other risks we face throughout this Form 10-K particularly in the “Business Environment” sections preceding our discussion of the operating results of our subsidiaries’ businesses below in Item 7. You should understand that it is not possible to predict or identify all

5

Table of Contents
risk factors. Consequently, you should not consider the following to be a complete discussion of all potential risks or uncertainties. We do not undertake to update any forward-looking statement that we may make from time to time except as required by applicable law.
Risks Related to Litigation, Legislative or Regulatory Action
Unfavorable litigation outcomes could materially adversely affect the consolidated results of operations, cash flows or financial position of Altria or the businesses of one or more of its subsidiaries or investees.
Legal proceedings covering a wide range of matters are pending or threatened in various United States and foreign jurisdictions against Altria and its subsidiaries, including PM USA and USSTC, as well as their respective indemnitees, indemnitors and Altria’s investees. Various types of claims may be raised in these proceedings, including product liability, unfair trade practices, antitrust, tax, contraband-related claims, patent infringement, employment matters, claims for contribution and claims of competitors, shareholders and distributors. Legislative action, such as changes to tort law, also may expand the types of claims and remedies available to plaintiffs.
Litigation is subject to uncertainty and it is possible that there could be adverse developments in pending or future cases. An unfavorable outcome or settlement of pending tobacco-related or other litigation could encourage the commencement of additional litigation. Damages claimed in some tobacco-related or other litigation are significant and, in certain cases, have ranged in the billions of dollars. The variability in pleadings in multiple jurisdictions, together with the actual experience of management in litigating claims, demonstrate that the monetary relief that may be specified in a lawsuit bears little relevance to the ultimate outcome.
In certain cases, plaintiffs claim that defendants’ liability is joint and several. In such cases, Altria or its subsidiaries may face the risk that one or more co-defendants decline or otherwise fail to participate in the bonding required for an appeal or to pay their proportionate or jury-allocated share of a judgment. As a result, Altria or its subsidiaries under certain circumstances may have to pay more than their proportionate share of any bonding- or judgment-related amounts. Furthermore, in those cases where plaintiffs are successful, Altria or its subsidiaries may also be required to pay interest and attorneys’ fees.
Although PM USA has historically been able to obtain required bonds or relief from bonding requirements in order to prevent plaintiffs from seeking to collect judgments while adverse verdicts have been appealed, there remains a risk that such relief may not be obtainable in all cases. This risk has been substantially reduced given that 47 states and Puerto Rico now limit the dollar amount of bonds or require no bond at all. As discussed in Note 18. Contingencies to the consolidated financial statements in Item 8 (“Note 18”), tobacco litigation plaintiffs have challenged the constitutionality of Florida’s bond cap statute in several cases and plaintiffs may challenge state bond cap statutes in other jurisdictions as well. Such challenges may include the applicability of state bond caps in federal court. Although we cannot predict the outcome of such challenges, it is possible that the consolidated results of operations, cash flows or financial position of Altria, or the businesses of one or more of its subsidiaries or investees, could be materially adversely affected in a particular fiscal quarter or fiscal year by an unfavorable outcome of one or more such challenges.
In certain litigation, Altria, its subsidiaries and its investees may face potentially significant non-monetary remedies that could have a material adverse effect on our businesses. For example, in the lawsuit brought by the United States Department of Justice discussed in Note 18, the district court did not impose monetary penalties but ordered significant non-monetary remedies, including the issuance of “corrective statements.” In the patent lawsuit pending before the United States International Trade Commission (“ITC”) discussed in Note 18, the plaintiffs seek a prohibition on the importation of the IQOS electronic device, HeatSticks and component parts into the United States. Additionally the on! transaction, discussed in Note 1. Background and Basis of Presentation to the consolidated financial statements in Item 8 (“Note 1”), had been the subject of an arbitration, which the parties agreed to settle for an immaterial amount to Altria in February 2021. An adverse outcome in the arbitration could have adversely affected Helix’s ability to compete effectively with oral nicotine pouches.
In 2019, we determined that our investment in JUUL was impaired in part due to the increase in the number and type of legal cases pending against JUUL. Altria and PM USA are also defendants in many of these cases. In addition, in April 2020 the FTC issued an administrative complaint against Altria and JUUL alleging that Altria’s 35% investment in JUUL and the associated agreements constitute unreasonable restraint on trade. E-vapor litigation and the FTC action, including the remedies the FTC is seeking, are further discussed in Note 18.
Altria and its subsidiaries have achieved substantial success in managing litigation. Nevertheless, litigation is subject to uncertainty, and significant challenges remain.
It is possible that the consolidated results of operations, cash flows or financial position of Altria, or the businesses of one or more of its subsidiaries or investees, could be materially adversely affected in a particular fiscal quarter or fiscal year by an unfavorable outcome or settlement of certain pending litigation. Altria and each of its subsidiaries named as a defendant believe, and each has been so advised by counsel handling the respective cases, that it has valid defenses to the litigation pending against it, as well as valid bases for appeal of adverse verdicts. Each of the companies has defended, and will continue to defend, vigorously against litigation challenges. However, Altria and its subsidiaries may enter into settlement discussions in particular cases if they believe it is in the best interests of Altria to do so. See Item 3. Legal Proceedings (“Item 3”), Note 18 and Exhibits 99.1 and 99.2 to this Form 10-K for a discussion of pending tobacco-related litigation.

6

Table of Contents
Significant federal, state and local governmental actions, including actions by the FDA, and various private sector actions may continue to have an adverse impact on us and our tobacco subsidiaries’ or our investees’ businesses and sales volumes.
As described in Tobacco Space - Business Environment in Item 7, PM USA faces significant governmental and private sector actions, including efforts aimed at reducing the incidence of tobacco use and efforts seeking to hold PM USA responsible for the adverse health effects associated with both smoking and exposure to environmental tobacco smoke. These actions, combined with the diminishing social acceptance of smoking, have resulted in reduced cigarette industry volume, and we expect that these factors will continue to reduce cigarette consumption levels.
More broadly, actions by the FDA and other federal, state or local governments or agencies, including those specific actions described in Tobacco Space - Business Environment in Item 7, may (i) impact the adult tobacco consumer acceptability of or access to tobacco products (for example, through nicotine or constituent limits or menthol or other flavor bans), (ii) limit adult tobacco consumer choices, (iii) delay or prevent the launch of new or modified tobacco products or products with claims of reduced risk, (iv) require the recall or other removal of tobacco products from the marketplace (for example as a result of (a) product contamination, (b) legislation and rulemaking that bans menthol or other flavors, (c) a determination by the FDA that one or more tobacco products do not satisfy the statutory requirements for substantial equivalence, (d) because the FDA requires that a currently marketed tobacco product proceed through the pre-market review process or (e) because the FDA does not authorize a PMTA or otherwise determines that removal is necessary for the protection of public health), (v) restrict communications to adult tobacco consumers, (vi) restrict the ability to differentiate tobacco products, (vii) create a competitive advantage or disadvantage for certain tobacco companies, (viii) impose additional manufacturing, labeling or packing requirements, (ix) interrupt manufacturing or otherwise significantly increase the cost of doing business or (x) restrict or prevent the use of specified tobacco products in certain locations or the sale of tobacco products by certain retail establishments. Any one or more of these actions may have a material adverse impact on the business, consolidated results of operations, cash flows or financial position of Altria and its tobacco subsidiaries, including adversely affecting Altria’s investment in JUUL. See Tobacco Space - Business Environment in Item 7 for a more detailed discussion.
Tobacco products are subject to substantial taxation, which could have an adverse impact on sales of the tobacco products of Altria’s tobacco subsidiaries.
Tobacco products are subject to substantial excise taxes, and significant increases in tobacco product-related taxes or fees have been proposed or enacted and are likely to continue to be proposed or enacted within the United States at the federal, state and local levels. The frequency and magnitude of excise tax increases can be influenced by various factors, including federal and state budgets (which have been negatively impacted by the COVID-19 pandemic) and the composition of executive and legislative bodies. Tax increases are expected to continue to have an adverse impact on sales of the tobacco products of our tobacco subsidiaries through lower consumption levels and the potential shift in adult consumer purchases from the premium to the non-premium or discount segments or to other low-priced or low-taxed tobacco products or to counterfeit and contraband products. Such shifts may also have an adverse impact on the reported share performance of tobacco products of Altria’s tobacco subsidiaries. For further discussion, see Tobacco Space - Business Environment - Excise Taxes in Item 7.
Unfavorable outcomes of any governmental investigations could materially affect the businesses of Altria and its subsidiaries or its investees.
From time to time, Altria, its subsidiaries and its investees are subject to federal and state governmental investigations on a range of matters. For further discussion of current pending investigations, see Tobacco Space - Business Environment - Other International, Federal, State and Local Regulation and Governmental and Private Activity in Item 7. We cannot predict the outcome of any such investigation, and it is possible that our business or the businesses of our investees could be materially adversely affected by an unfavorable outcome of any current or future investigation.
A challenge to our tax positions or an increase in the income tax rate could adversely affect our earnings or cash flow.
Tax laws and regulations, such as the 2017 Tax Cuts and Jobs Act (the “Tax Reform Act”), are complex and subject to varying interpretations. A successful challenge to one or more of Altria’s tax positions (which could give rise to additional liabilities, including interest and potential penalties) or an increase in the corporate income tax rate could adversely affect our earnings or cash flow.
International business operations subject Altria and its subsidiaries to various United States and foreign laws and regulations, and violations of such laws or regulations could result in reputational harm, legal challenges and/or significant costs.
While Altria and its subsidiaries are primarily engaged in business activities in the United States, they do engage (directly or indirectly) in certain international business activities that are subject to various United States and foreign laws and regulations, such as foreign privacy laws, the U.S. Foreign Corrupt Practices Act and other laws prohibiting bribery and corruption. Although we have a Code of Conduct and a compliance system designed to prevent and detect violations of applicable law, no system can provide assurance that it will always protect against improper actions by employees, investees or third parties. Violations of these laws, or allegations of such violations, could result in reputational harm, legal challenges and/or significant costs.

7

Table of Contents
Risks Related to Our Businesses
Altria, its subsidiaries and its investees face various risks related to health epidemics and pandemics, including the COVID-19 pandemic and similar outbreaks, which could have a material adverse effect on the business, consolidated results of operations, cash flows or financial position of Altria and its subsidiaries and investees.
Altria’s, its subsidiaries’ and its investees’ business and financial results, consolidated results of operations, cash flows or financial position could be negatively impacted by health epidemics, pandemics and similar outbreaks. The spreading COVID-19 pandemic could have negative impacts, such as (i) a global or U.S. recession or other economic crisis, including a financial crisis, (ii) credit and capital markets volatility (and access to these markets, including by those in the distribution and supply chains), (iii) significant volatility in demand for our tobacco and wine subsidiaries’ and investees’ products, (iv) changes in adult consumer accessibility to those products, including due to government action, (v) changes in adult consumer behavior and preferences, including trading down to lower-priced products or cessation of product use due to public health actions or concerns and economic conditions (including those stemming from potential changes in government stimulus or reductions in unemployment payments or other benefits), and (vi) extended or multiple disruptions in our subsidiaries’ or investees’ manufacturing operations, or in their distribution and supply chains. In addition, our subsidiaries’ and investees’ operations may incur increased costs and otherwise be negatively affected if significant portions of their respective workforces (or the workforces within their respective distribution or supply chains) are unable to work or work effectively, including because of illness, unavailability of personal protective equipment, quarantines, government actions, facility closures or other restrictions.
The impact of the COVID-19 pandemic depends on factors beyond our knowledge or control, including the duration and severity of the outbreak, increases in the number of cases in future periods, and actions taken to contain its spread and mitigate the public health effects. We cannot at this time predict the impact of the COVID-19 pandemic on our or our investees’ future financial or operational results, but the impact could be material over time. See the risks below related to extended disruptions at a facility, of a distributor or in service by a service provider and the risks related to our investment in ABI and the earnings from and carrying value of that investment. For further discussion on the impact of the COVID-19 pandemic on the tobacco and wine businesses, see Tobacco Space - Business Environment and Wine Segment - Business Environment in Item 7.
Our tobacco businesses face significant competition (including across categories) and their failure to compete effectively could have an adverse effect on the consolidated results of operations or cash flows of Altria, or the business of Altria’s tobacco subsidiaries.
Each of Altria’s tobacco subsidiaries operates in highly competitive tobacco categories. This competition also exists across categories as adult tobacco consumer preferences evolve. Significant methods of competition include product quality, taste, price, product innovation, marketing, packaging, distribution and promotional activities. This highly competitive environment could negatively impact the profitability, market share and shipment volume of our tobacco subsidiaries, which could have an adverse effect on the consolidated results of operations or cash flows of Altria. See Tobacco Space - Business Environment - Summary in Item 7 for additional discussion concerning evolving adult tobacco consumer preferences. Growth of the e-vapor product category and other innovative tobacco products, including oral nicotine pouches, has further contributed to reductions in cigarette consumption levels and cigarette industry sales volume and has adversely affected the growth rates of other tobacco products, including smokeless tobacco. In addition, growth of unregulated synthetic nicotine products, which may not be subject to the same regulatory restrictions (including marketing restrictions and FDA pre-marketing requirements) as the tobacco-derived oral nicotine products of Altria’s tobacco subsidiaries, could negatively impact the growth of our oral nicotine pouch products. Continued growth in these categories could have a material adverse impact on the business, results of operations, cash flows or financial position of Altria and its tobacco subsidiaries.
PM USA also faces competition from lower-priced brands sold by certain United States and foreign manufacturers that have cost advantages because they are not parties to settlements of certain tobacco litigation in the United States and, as such, are not required to make annual settlement payments as required by the parties to the settlements. These settlement payments are significant for PM USA, as described in Debt and Liquidity - Payments under State Settlement Agreements and FDA Regulation in Item 7. These settlements, among other factors, resulted in substantial cigarette price increases to help cover the cost of the settlement payments. Manufacturers not party to the settlements are subject to state escrow legislation requiring escrow deposits. Such manufacturers may avoid these escrow obligations by concentrating on certain states where escrow deposits are not required or are required on fewer than all such manufacturers’ cigarettes sold in such states. Additional competition has resulted from diversion into the United States market of cigarettes intended for sale outside the United States, the sale of counterfeit cigarettes by third parties, the sale of cigarettes by third parties over the Internet and by other means designed to avoid collection of applicable taxes, and imports of foreign lower-priced brands. USSTC faces significant competition in the smokeless tobacco category and has experienced consumer down-trading to lower-priced competitive brands.

8

Table of Contents
Altria and its subsidiaries may be unsuccessful in anticipating changes in adult consumer preferences, responding to changes in consumer purchase behavior or managing through difficult competitive and economic conditions, which could have an adverse effect on the consolidated results of operations and cash flows of Altria or the business of Altria’s tobacco and wine subsidiaries.
Each of our tobacco and wine subsidiaries is subject to intense competition and changes in adult consumer preferences. To be successful, they must continue to:
promote brand equity successfully;
anticipate and respond to new and evolving adult consumer preferences;
develop, manufacture, market and distribute new and innovative products that appeal to adult consumers (including, where appropriate, through arrangements with, or investments in, third parties);
improve productivity; and
protect or enhance margins through cost savings and price increases.
See Tobacco Space - Business Environment - Summary in Item 7 and the immediately preceding risk factor for additional discussion concerning evolving adult tobacco consumer preferences, specifically the growth of e-vapor and other innovative tobacco products and the effects on our tobacco operating companies.
See Wine Segment - Business Environment - Summary in Item 7 for additional discussion concerning evolving adult alcohol consumer preferences; specifically the slowing of the premium wine category and the effects on our wine subsidiaries.
The willingness of adult consumers to purchase premium consumer product brands depends in part on economic conditions. In periods of economic uncertainty, adult consumers may purchase more discount brands and/or, in the case of tobacco products, consider lower-priced tobacco products, which could have a material adverse effect on the business, consolidated results of operations, cash flows or financial position of Altria and its subsidiaries. While our tobacco and wine subsidiaries work to broaden their brand portfolios to compete effectively with lower-priced products, the failure to do so could negatively impact our companies’ ability to compete in these circumstances.
Our financial services business (conducted through PMCC) holds investments in finance leases, principally in transportation (including aircraft), power generation, real estate and manufacturing equipment. Its lessees are subject to significant competition and uncertain economic conditions. If parties to PMCC’s leases fail to manage through difficult economic and competitive conditions, PMCC may have to increase its allowance for losses, which would adversely affect our earnings.
Altria’s tobacco subsidiaries and investees may be unsuccessful in developing and commercializing adjacent products or processes, including innovative tobacco products that may reduce the health risks associated with certain other tobacco products and that appeal to adult tobacco consumers, which may have an adverse effect on their ability to grow new revenue streams and/or put them at a competitive disadvantage.
Altria and its subsidiaries have growth strategies involving moves and potential moves into adjacent products or processes, including innovative tobacco products. Some innovative tobacco products may reduce the health risks associated with certain other tobacco products, while continuing to offer adult tobacco consumers (within and outside the United States) products that meet their taste expectations and evolving preferences. Examples include tobacco-containing and nicotine-containing products that reduce or eliminate exposure to cigarette smoke and/or constituents identified by public health authorities as harmful, such as electronically heated tobacco products, oral nicotine pouches, and e-vapor products.
In addition to internal product development, these efforts include arrangements with, or investments in, third parties such as our arrangement with PMI to commercialize IQOS and related HeatStick products in the United States, which is governed by an exclusive license and distribution agreement. The initial 5-year term of this agreement expires in April 2024 and renews at our option for an additional 5-year period so long as we achieve certain performance objectives. The initial term performance objectives are based on achieving 0.5% dollar share of the cigarette category within a certain period of time in a certain number of geographic areas. In addition, to maintain our exclusive distribution rights as to PMI during the term of the agreement, we must achieve certain performance objectives within a specified time period by April 2022. The exclusive distribution rights performance objectives are based on achieving 0.5% dollar share of the cigarette category within a certain period of time in a single geographic area. While we believe Altria will meet the initial term and exclusive distribution rights performance objectives, it is possible that we may not meet them or that we may have a disagreement with PMI as to whether those objectives have been met. In either case, it could result in the loss of (i) our unilateral right to extend the agreement for the additional 5-year period, and therefore we would no longer be able to commercialize IQOS and related HeatStick products after April 2024, or (ii) our exclusive distribution rights as to PMI.
Additionally, our investment in JUUL subjects us to non-competition obligations restricting us from investing or engaging in the e-vapor business other than through JUUL, subject to certain exceptions.
Our tobacco subsidiaries and investees may not succeed in their efforts to develop and commercialize these adjacent products, which would have an adverse effect on the ability to grow new revenue streams.

9

Table of Contents
Further, we cannot predict whether regulators, including the FDA, will permit the marketing or sale of any particular innovative products (including products with claims of reduced risk to adult consumers), the speed with which they may make such determinations or whether regulators will impose an unduly burdensome regulatory framework on such products. In addition, the FDA could, for a variety of reasons, determine that innovative products currently on the market but pending FDA review of the associated PMTA (such as on! oral nicotine pouches), or those that have previously received authorization, including with a claim of reduced exposure (such as IQOS), are not appropriate for the public health and the FDA could require such products be taken off the market. See Tobacco Space - Business Environment - FSPTCA and FDA Regulation in Item 7 for further discussion. We also cannot predict whether these products will appeal to adult tobacco consumers or whether adult tobacco consumers’ purchasing decisions would be affected by reduced-risk claims on such products if permitted. Adverse developments on any of these matters could negatively impact the commercial viability of such products.
If our tobacco subsidiaries or investees do not succeed in their efforts to develop and commercialize innovative tobacco products or to obtain regulatory approval for the marketing or sale of products, including with claims of reduced risk, but one or more of their competitors does succeed, our tobacco subsidiaries or investees may be at a competitive disadvantage, which could have an adverse effect on their financial performance.
Significant changes in price, availability or quality of tobacco, other raw materials or component parts could have an adverse effect on the profitability and business of Altria’s tobacco subsidiaries and investees.
Any significant change in prices, quality or availability of tobacco, other raw materials or component parts, including as a result of the COVID-19 pandemic, could adversely affect our tobacco subsidiaries’ and our investees’ profitability and business. The COVID-19 pandemic also may impact the availability of direct materials necessary for our tobacco subsidiaries and JUUL to remain compliant with FDA and other regulatory requirements for tobacco products. For further discussion, see Tobacco Space - Business Environment - Price, Availability and Quality of Tobacco, Other Raw Materials and Component Parts in Item 7.
Altria’s subsidiaries rely on a few significant facilities and a small number of key suppliers, distributors and distribution chain service providers. An extended disruption at a facility or in service by a supplier, distributor or distribution chain service provider could have a material adverse effect on the business, the consolidated results of operations, cash flows or financial position of Altria and its tobacco and wine subsidiaries and investees.
Altria’s subsidiaries face risks inherent in reliance on a few significant manufacturing facilities and a small number of key suppliers, distributors and distribution chain service providers. A natural or man-made disaster or other disruption that affects the manufacturing operations of any of Altria’s tobacco or wine subsidiaries or investees, the operations of any key supplier, distributor or distribution chain service provider of any of Altria’s tobacco or wine subsidiaries or investees or any other disruption in the supply or distribution of goods or services (including a key supplier’s inability to comply with government regulations or unwillingness to supply goods or services to a tobacco company) could adversely impact the operations of the affected subsidiaries and investees. For example, in March 2020, the COVID-19 pandemic resulted in a temporary suspension of operations at PM USA’s Richmond, Virginia manufacturing facility, which is the primary facility for manufacturing PM USA cigarettes. Some state governors also have issued executive orders requiring that certain businesses temporarily suspend operations for varying periods of time while the COVID-19 pandemic persists. Operations of our subsidiaries, suppliers, distributors and distribution chain service providers and those of our investees could be suspended temporarily once or multiple times, or closed permanently, depending on various factors, including how long the COVID-19 pandemic persists and the extent to which state, local and federal governments, as well as foreign countries, impose restrictions on the operation of facilities or otherwise place limits on the supply and distribution chains. An extended disruption in operations experienced by one or more of Altria’s subsidiaries, investees or in the supply or distribution of goods or services by one or more key suppliers, distributors or distribution chain service providers could have a material adverse effect on the business, the consolidated results of operations, cash flows or financial position of Altria and its tobacco and wine subsidiaries and investees.
Altria’s subsidiaries could decide or be required to recall products, which could have a material adverse effect on the business, reputation, consolidated results of operations, cash flows or financial position of Altria and its subsidiaries.
In addition to a recall required by the FDA, as referenced above, our subsidiaries could decide, or other laws or regulations could require them, to recall products due to the failure to meet quality standards or specifications, suspected or confirmed and deliberate or unintentional product contamination, or other adulteration, product misbranding or product tampering. Product recalls could have a material adverse effect on the business, reputation, consolidated results of operations, cash flows or financial position of Altria and its subsidiaries.
The failure of Altria’s information systems or service providers’ information systems to function as intended, or cyber-attacks or security breaches, could have a material adverse effect on the business, reputation, consolidated results of operations, cash flows or financial position of Altria and its subsidiaries.
Altria and its subsidiaries rely extensively on information systems, many of which are managed by third-party service providers (such as cloud providers), to support a variety of business processes and activities, including: complying with regulatory, legal, financial reporting and tax requirements; engaging in marketing and e-commerce activities; managing and improving the effectiveness of our operations; manufacturing and distributing our products; collecting and storing sensitive data and confidential information; and

10

Table of Contents
communicating internally and externally with employees, investors, suppliers, trade customers, adult consumers and others. We continue to make investments in administrative, technical and physical safeguards to protect our information systems and data from cyber-threats, including human error and malicious acts. Our safeguards include employee training, testing and auditing protocols, backup systems and business continuity plans, maintenance of security policies and procedures, monitoring of networks and systems, and third-party risk management.
To date, interruptions of our information systems have been infrequent and have not had a material impact on our operations. However, because technology is increasingly complex and cyber-attacks are increasingly sophisticated and more frequent, there can be no assurance that such incidents will not have a material adverse effect on us in the future. Failure of our systems or service providers’ systems to function as intended, or cyber-attacks or security breaches, could result in loss of revenue, assets, personal data, intellectual property, trade secrets or other sensitive and confidential data, violation of applicable privacy and data security laws, damage to the reputation of our companies and their brands, operational disruptions, legal challenges and significant remediation and other costs to Altria and its subsidiaries.
Altria may be unable to attract and retain the best talent due to the impact of decreasing social acceptance of tobacco usage, tobacco control actions and other factors.
Our ability to implement our strategy of attracting and retaining the best talent may be impaired by the impact of decreasing social acceptance of tobacco usage and tobacco regulation and control actions. The tobacco industry competes for talent with the consumer products industry and other companies that may enjoy greater societal acceptance and fewer longer-term challenges. As a result, we may be unable to attract and retain the best talent.
Altria may be required to write down intangible assets, including goodwill, due to impairment, which could have a material adverse effect on our results of operations or financial position.
We periodically calculate the fair value of our reporting units and intangible assets to test for impairment. This calculation may be affected by several factors, including general economic conditions (such as continued uncertainty of the COVID-19 pandemic), regulatory developments, changes in category growth rates as a result of changing adult consumer preferences, success of planned new product expansions, competitive activity and income and excise taxes. Certain events also can trigger an immediate review of intangible assets. If an impairment is determined to exist in either situation, we will incur impairment losses, which could have a material adverse effect on our results of operations or financial position. For further discussion, see Discussion and Analysis - Critical Accounting Policies and Estimates in Item 7.
Competition, changes in adult consumer preferences, unfavorable changes in grape supply and new governmental regulations or revisions to existing governmental regulations could adversely affect Ste. Michelle’s wine business.
Ste. Michelle’s business is impacted by evolving adult consumer preferences. Shifts away from the wine category to other alcohol categories or shifts to lower-priced wines have resulted, and could continue to result, in slowing growth in Ste. Michelle’s sales and increased inventory levels and have a material adverse effect on Ste. Michelle’s wine business. As discussed in Note 5. Asset Impairment, Exit and Implementation Costs to the consolidated financial statements in Item 8 (“Note 5”), during the year ended December 31, 2020, as a result of inventory levels significantly exceeding long-term forecasted demand, Ste. Michelle recorded pre-tax charges of $411 million in cost of sales, including a $292 million inventory write off, $100 million in estimated losses on future non-cancelable grape purchase commitments and $19 million in inventory disposal costs and other charges. Evolving adult consumer preferences, an economic downturn or recession or other factors could result in a further slowdown in the wine category and otherwise have a material adverse effect on Ste. Michelle’s wine business.
The adequacy of Ste. Michelle’s grape supply is influenced by consumer demand for wine in relation to industry-wide production levels as well as by weather and crop conditions, particularly in eastern Washington. Supply shortages or surpluses related to any one or more of these factors could impact production costs and wine prices, which ultimately may have a negative impact on Ste. Michelle’s sales. In addition, Ste. Michelle’s business is subject to significant competition, including from many large, well-established domestic and international companies. Federal, state and local governmental agencies also regulate the alcohol beverage industry through various means, including licensing requirements, pricing, labeling and advertising restrictions, and distribution and production policies. New regulations or revisions to existing regulations, resulting in further restrictions or taxes on the manufacture and sale of alcoholic beverages may have an adverse effect on Ste. Michelle’s wine business. For further discussion see Wine Segment - Business Environment in Item 7.
Risks Related to the Capital Markets and Financing
Acquisitions or other events may adversely affect Altria’s credit rating, and Altria may not achieve its anticipated strategic or financial objectives of a transaction.
From time to time, Altria considers acquisitions, investments or dispositions and may engage in confidential negotiations that are not publicly announced unless and until those negotiations result in a definitive agreement. Although we seek to maintain or improve our credit ratings over time, it is possible that completing a given acquisition, investment, disposition or the occurrence of other events could negatively impact our investment grade credit ratings or the outlook for those ratings as occurred following our investment in JUUL.

11

Table of Contents
Any such change in ratings or outlook may negatively affect the amount of credit available to us and also may increase our costs and adversely affect our earnings or our dividend rate. Furthermore, acquisition opportunities are limited, and acquisitions present risks of failing to achieve efficient and effective integration, strategic objectives and anticipated revenue improvements and cost savings. There can be no assurance that we will be able to acquire attractive businesses on favorable terms or that we will realize any of the anticipated benefits from an acquisition or an investment. Additionally, there can be no assurance that we will be able to dispose of our businesses or investments on favorable terms, which may result in a loss in Altria’s consolidated statements of earnings (losses).
Disruption and uncertainty in the credit and capital markets could adversely affect Altria’s access to these markets, earnings and dividend rate.
Access to the credit and capital markets is important for us to satisfy our liquidity and financing needs. For example, we typically access the commercial paper market early in the second quarter to help fund payments under the Master Settlement Agreement, tax obligations and shareholder dividends. Disruption and uncertainty in these markets and any resulting adverse impact on credit availability, pricing, credit terms or credit rating may negatively affect the amount of credit available to us and may also increase our costs and adversely affect our earnings or our dividend rate.
Altria may be unable to attract investors due to the impact of decreasing social acceptance of tobacco usage.
There is increasing investor focus on environmental, social and governance (“ESG”) matters. Organizations that provide ESG information to investors have developed ratings processes for evaluating companies on their approach to ESG matters. Such ratings are used by some investors to inform their investment and voting decisions. Decreasing social acceptance of tobacco products or unfavorable ESG ratings may lead to increased negative investor sentiment toward Altria, which could result in shareholders choosing to divest their ownership in Altria stock or choosing not to invest in our stock and could have a negative impact on the market performance of our stock.
Risks Related to Our Investments
A challenge to our investment in JUUL, if successful, could result in a broad range of resolutions, including divestiture of the investment or rescission of the transaction.
A challenge to our investment in JUUL, if successful, could result in a broad range of resolutions such as divestiture of the investment or rescission of the transaction. In April 2020, the FTC issued an administrative complaint against Altria and JUUL alleging that Altria’s 35% investment in JUUL and the associated agreements constitute an unreasonable restraint of trade in violation of Section 1 of the Sherman Act and Section 5 of the FTC Act, and substantially lessened competition in violation of Section 7 of the Clayton Act. The FTC seeks a broad range of remedies, including divestiture of Altria’s investment in JUUL, rescission of the transaction and prohibition against any officer or director of either Altria or JUUL serving on the other’s board of directors or attending meetings. The administrative trial will take place before an FTC administrative law judge and is currently scheduled to begin June 2021. Any ruling by the FTC is subject to review by the FTC Commissioners and subsequently by a federal appellate court if appealed.
Also, various putative class action lawsuits have been filed against Altria (and in some cases, subsidiaries of Altria) and JUUL. The lawsuits cite the FTC administrative complaint referenced above and allege claims similar to those made by the FTC. Plaintiffs in these lawsuits are seeking various remedies, including treble damages, attorneys’ fees, a declaration that the agreements between Altria and JUUL are invalid, divestiture of Altria’s investment in JUUL and rescission of the transaction.
A successful challenge by the FTC or the plaintiffs in the lawsuits to the investment would adversely affect us, including by eliminating, or substantially limiting, our rights with respect to our investment in JUUL. For further discussion see Note 18.
The expected benefits of the JUUL transaction may not materialize in the expected manner or timeframe or at all.
Regardless of whether antitrust clearance is obtained, the expected benefits of the JUUL transaction may not materialize in the expected manner or timeframe or at all, including due to the risks encountered by JUUL in its business, such as operational risks, competitive risks and regulatory and legislative risks at the international, federal, state and local levels, including actions by the FDA, and adverse publicity due to underage use of e-vapor products and other factors; unanticipated impacts on JUUL’s relationships with employees, customers, suppliers and other third parties; potential disruptions to JUUL’s management or current or future plans and operations; or domestic or international litigation developments, investigations, or otherwise. As discussed in Note 18, JUUL and Altria and/or its subsidiaries, including PM USA, are named as defendants in various individual and class action lawsuits. JUUL also is named in a significant number of additional individual and class action lawsuits to which neither Altria nor its subsidiaries is a party. See Tobacco Space - Business Environment in Item 7 for a discussion of certain FDA-related regulatory risks applicable to the e-vapor category, including the potential removal of certain e-vapor products from the market as a result of FDA enforcement action and the potential denial of new tobacco product applications for e-vapor products. Failure to realize the expected benefits of our JUUL investment could adversely affect the value of the investment.
As discussed in Investments in Equity Securities in Note 6, as part of the preparation of our financial statements for the quarters ended September 30, 2019, December 31, 2019 and September 30, 2020, we performed valuations of our investment in JUUL as a result of the existence of impairment indicators. As a result, we determined that our investment in JUUL was impaired and recorded total non-cash

12

Table of Contents
pre-tax impairment charges of $11.2 billion. Following Share Conversion in the fourth quarter of 2020, Altria elected to account for its equity method investment in JUUL under the fair value option. Under this option, Altria’s consolidated statements of earnings (losses) include any cash dividends received from its investment in JUUL and any changes in the fair value of its investment, which is calculated quarterly. While we believe the December 31, 2020 valuation of $1.7 billion is the appropriate current fair value of our investment, the risks identified in this paragraph, some of which are also further discussed in Discussion and Analysis - Investments in JUUL and Tobacco Space - Business Environment in Item 7 and in Note 18, are ongoing with respect to the current fair value. Quarterly fair value changes could create volatility in Altria’s consolidated financial position and earnings and, if the fair value of our investment in JUUL decreases, it could have a material adverse effect on Altria’s consolidated financial position or earnings.
Our investment in JUUL includes non-competition, standstill and transfer restrictions that prevent us from gaining control of JUUL. Furthermore, if we elect not to extend our non-competition obligations beyond December 20, 2024, we would lose certain of our governance, consent, preemptive and other rights with respect to our investment in JUUL.
The shares of JUUL we hold generally cannot be sold or otherwise transferred until December 20, 2024, subject to limited exceptions. We also generally agreed not to compete with JUUL in the e-vapor category until at least December 20, 2024, which may be extended at our election. If, however, JUUL is prohibited by federal law from selling e-vapor products in the U.S. for at least one year or if Altria’s carrying value of the JUUL investment is not more than 10% of its initial carrying value of $12.8 billion, we may elect to compete with JUUL in the e-vapor category prior to December 20, 2024. In addition, in the event we elect to exercise our board designation rights at JUUL, JUUL’s board of directors will include nine members, three of whom will be designated by Altria, including one independent designee. JUUL’s strategy and its material decisions are not and will not be controlled by us, and the terms of our agreements with JUUL mean that we are required to bear the risks associated with our investment in JUUL and are restricted from competing with JUUL until at least December 20, 2024, subject to the exceptions mentioned above. Further, if we elect not to extend our non-competition obligations beyond that date or to terminate such obligations in the circumstances described above, we would lose some or all of our board designation rights, preemptive rights, consent rights and other rights with respect to our investment in JUUL. Loss of these rights could adversely affect us by impairing our ability to influence JUUL.
Altria’s reported earnings from and carrying value of its equity investment in ABI and the dividends paid by ABI on shares owned by Altria may be adversely affected by various factors, including foreign currency exchange rates and ABI’s business results, including as a result of the COVID-19 pandemic, and stock price. In addition, if the carrying value of our investment in ABI exceeds its fair value and the loss in value is other than temporary, the investment is considered impaired, which would result in impairment losses.
For purposes of financial reporting, the earnings from and carrying value of our equity investment in ABI are translated into U.S. dollars (“USD”) from various local currencies. In addition, ABI pays dividends in euros, which we convert into USD. During times of a strengthening USD against these currencies, our reported earnings from and carrying value of our equity investment in ABI will be reduced because these currencies will translate into fewer USD and the dividends that we receive from ABI will convert into fewer USD. Dividends and earnings from and carrying value of our equity investment in ABI are also subject to the risks encountered by ABI in its business, its business outlook, cash flow requirements and financial performance, the state of the market and the general economic climate, including the impact of the COVID-19 pandemic. For example, in 2020, as a result of the uncertainty, volatility and impact of the COVID-19 pandemic on ABI’s business, ABI reduced by 50% its final 2019 dividend paid in the second quarter of 2020 and did not pay its interim 2020 dividend that would have been paid in the fourth quarter of 2020, which resulted in a reduction of cash dividends Altria received from ABI.
In addition, since October 2019, the carrying value of our investment in ABI has exceeded the fair value of our equity investment in ABI. We concluded at December 31, 2020, that the decline in fair value of our investment in ABI below its carrying value continues to be temporary. If, however, the carrying value of our investment in ABI exceeds its fair value and the loss in value is other than temporary, the investment is considered impaired, which would result in impairment losses and could have a material adverse effect on Altria’s consolidated financial position or earnings. We cannot provide any assurance that ABI will successfully execute its business plans and strategies. Earnings from and carrying value of our equity investment in ABI are also subject to fluctuations in ABI’s stock price. See Note 6 for further discussion.
We received a substantial portion of our consideration from the October 2016 SABMiller plc (“SABMiller”)/ABI business combination (“ABI Transaction”) in the form of restricted shares subject to a five-year lock-up. Furthermore, if our percentage ownership in ABI were to decrease below certain levels, we may be subject to additional tax liabilities, incur a reduction in the number of directors that we can have appointed to the ABI Board of Directors and be unable to account for our investment under the equity method of accounting.
Upon completion of the ABI Transaction, we received a substantial portion of our consideration in the form of restricted shares that cannot be sold or transferred for a period of five years following the ABI Transaction, subject to limited exceptions. These transfer restrictions will require us to bear the risks associated with our investment in ABI for a five-year period that expires on October 10, 2021. Further, in the event that our ownership percentage in ABI were to decrease below certain levels, (i) we may be subject to additional tax liabilities, (ii) the number of directors that we have the right to have appointed to the ABI board of directors could be

13

Table of Contents
reduced from two to one or zero and (iii) we may be unable to continue to account for our investment in ABI under the equity method of accounting.
Tax authorities may challenge the tax treatment of the consideration Altria received in the ABI Transaction and the tax treatment of the ABI investment may not be as favorable as Altria anticipates.
While we expect the tax treatment of the consideration that we received from the ABI Transaction to be respected, the statute of limitations for the tax year in which the transaction occurred has not expired. Therefore, we cannot provide any assurance that federal and state tax authorities will not challenge the expected tax treatment and, if they do, what the outcome of any such challenge will be. In addition, there is a risk that the tax treatment of our investment in ABI may not be as favorable as we anticipate.
The expected benefits of the Cronos transaction may not materialize in the expected manner or timeframe or at all.
In March 2019, we acquired common shares representing a 45% equity interest in Cronos, a warrant to acquire common shares representing an additional 10% equity interest in Cronos and anti-dilution protections to purchase Cronos shares to maintain our ownership percentage. There can be no assurance that we will realize the expected benefits of the Cronos transaction, including due to the risks encountered by Cronos in its business, such as operational risks and legal and regulatory risks; unanticipated impacts on Cronos’s relationships with third parties, its management, or its current or future plans and operations due to the Cronos transaction or other factors; or domestic or international litigation developments, tax disputes, investigations, or otherwise; or that Cronos will successfully execute its business plans and strategies. Further, a failure by Cronos or Altria to comply with applicable laws, including cannabis laws, could result in criminal, civil or tax liability for Altria. If the carrying value of our investment in Cronos exceeds its fair value and the loss in value is other than temporary, the investment is considered impaired, which would result in impairment losses and could have a material adverse effect on Altria’s consolidated financial position or earnings.

Item 1B. Unresolved Staff Comments.
None.

Item 2. Properties.
At December 31, 2020, ALCS owned one property in Richmond, Virginia that serves as the headquarters facilities for Altria, PM USA, USSTC, Middleton, Helix and certain other subsidiaries.
At December 31, 2020, PM USA owned and operated a manufacturing facility located in Richmond, Virginia that PM USA uses in the manufacturing of cigarettes (smokeable products segment). PM USA leases portions of this facility to other Altria subsidiaries for use in the manufacturing of cigars (smokeable products segment) and MST, snus and oral nicotine pouch products (oral tobacco products segment). In addition, PM USA owned a research and technology center in Richmond, Virginia that is leased to ALCS.
At December 31, 2020, the oral tobacco products segment had various manufacturing and processing facilities, the most significant of which are located in Nashville, Tennessee.
At December 31, 2020, the wine segment owned and operated various wine-making facilities in Washington, California and Oregon.
The plants and properties owned or leased and operated by Altria and its subsidiaries are maintained in good condition and are believed to be suitable and adequate for present needs.

Item 3. Legal Proceedings.
The information required by this Item is included in Note 18 and Exhibits 99.1 and 99.2 to this Form 10-K. Altria’s consolidated financial statements and accompanying notes for the year ended December 31, 2020 were filed on Form 8-K on January 28, 2021 (such consolidated financial statements and accompanying notes are also included in Item 8). The following summarizes certain developments in Altria’s litigation since the filing of the Form 8-K.
Recent Developments
Engle Progeny Trial Results
In Berger (Cote), as a result of the Eleventh Circuit Court of Appeals’ decision affirming the punitive damages award, PM USA recorded a pre-tax provision of $21 million, including interest, for such award in the first quarter of 2021. PM USA previously recorded a pre-tax provision of approximately $6 million, including interest, for the compensatory damages award. PM USA paid these amounts, plus fees in the amount of $1.5 million, in February 2021.
In Santoro, as a result of the Florida Supreme Court’s denial of PM USA’s appeal of the punitive damages award, PM USA recorded a pre-tax provision of $0.1 million, including interest, for such award in the first quarter of 2021. PM USA previously recorded a pre-tax

14

Table of Contents
provision of approximately $0.8 million, including interest, for the compensatory damages award. In January 2021, PM USA paid the recorded amounts, plus fees and additional interest.
In Sommers, as a result of the Florida Third District Court of Appeals’ non-appealable decision affirming an award of attorneys’ fees, costs and interest, PM USA recorded a pre-tax provision of approximately $3 million, including interest, for such award in the first quarter of 2021.
Non-Engle Progeny Trial Results
In Greene, a case with a trial court judgment against PM USA for $30 million, in February 2021, the trial court awarded plaintiff attorneys’ fees and costs in the amount of approximately $2.3 million. In February 2021, PM USA served its post-trial motions, including to reverse the judgment or for a new trial.
In February 2021, the Massachusetts Supreme Judicial Court asserted jurisdiction over the appeal in Laramie.
Health Care Cost Recovery Litigation
NPM Adjustment Disputes: In connection with a proceeding pursuant to the New York settlement where an independent investigator was to determine the amounts due to the participating manufacturers from New York for 2019 and 2020, the investigator issued its determination in February 2021. Pursuant to that determination, PM USA expects to receive approximately $56 million in April 2021 and approximately the same amount in April 2022.
IQOS Litigation
In the lawsuit filed by RAI Strategic Holdings, Inc. and R.J. Reynolds Vapor Co. claiming patent infringement based on the sale of the IQOS electronic device and HeatSticks in the United States, the defendants filed counterclaims alleging that plaintiffs’ e-vapor products infringe patents owned by one or more defendants. In December 2020, the court stayed the case due to the COVID-19 pandemic. In February 2021, the court lifted the stay with respect to defendants’ counterclaims.
Antitrust Litigation
The FTC has postponed the administrative trial against Altria and JUUL, originally scheduled to begin in April 2021, until June 2021.

Item 4. Mine Safety Disclosures.
Not applicable.


15

Table of Contents
Part II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Performance Graph
The graph below compares the cumulative total shareholder return of Altria’s common stock for the last five years with the cumulative total return for the same period of the S&P 500 Index and the S&P Food, Beverage and Tobacco Industry Group Total Return Index. The graph assumes the investment of $100 in common stock and each of the indices as of the market close on December 31, 2015 and the reinvestment of all dividends on a quarterly basis.
mo-20201231_g1.jpg
DateAltriaS&P Food, Beverage & TobaccoS&P 500
December 2015$100.00 $100.00 $100.00 
December 2016$120.46 $108.76 $111.95 
December 2017$131.84 $122.19 $136.38 
December 2018$96.13 $103.96 $130.39 
December 2019$103.78 $129.88 $171.44 
December 2020$93.00 $137.10 $202.98 
Source: Bloomberg - “Total Return Analysis” calculated on a daily basis and assumes reinvestment of dividends as of the ex-dividend date.
Market and Dividend Information
The principal stock exchange on which Altria’s common stock (par value $0.33 1/3 per share) is listed is the New York Stock Exchange under the trading symbol “MO”. At February 15, 2021, there were approximately 54,000 holders of record of Altria’s common stock.
Altria has a history of paying cash dividends and expects to continue to do so with a long-term objective of a dividend payout ratio target of approximately 80% of its adjusted diluted earnings per share. Future dividend payments remain subject to the discretion of the Board of Directors.

16

Table of Contents
Issuer Purchases of Equity Securities During the Quarter Ended December 31, 2020
In July 2019, the Board of Directors authorized a $1.0 billion share repurchase program. In April 2020, the Board rescinded the $500 million remaining in this program as part of Altria’s efforts to enhance its liquidity position in response to the COVID-19 pandemic. There were no share repurchases made in 2020 under a publicly announced program. In January 2021, the Board authorized a new $2.0 billion share repurchase program, which Altria expects to complete by June 30, 2022. The timing of share repurchases under this program depends upon marketplace conditions and other factors, and the program remains subject to the discretion of the Board.
Altria’s share repurchase activity for each of the three months in the period ended December 31, 2020, was as follows:
Period
Total Number of Shares Purchased (1)
Average Price Paid Per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or ProgramsApproximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs
October 1- October 31, 2020836 $37.17  $ 
November 1- November 30, 2020 $  $ 
December 1- December 31, 202024 $43.00  $ 
For the Quarter Ended December 31, 2020860 $37.33  
(1) The total number of shares purchased represents shares withheld by Altria in an amount equal to the statutory withholding taxes for vested stock-based awards previously granted to eligible employees.
Item 6. Selected Financial Data.
Item 6 has been omitted because it is no longer required as a result of recent amendments to Regulation S-K.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion should be read in conjunction with the other sections of this Form 10-K, including the consolidated financial statements and related notes contained in Item 8, and the discussion of risk factors that may affect future results in Item 1A.
Description of the Company
For a description of Altria, see Item 1. Business, and Background in Note 1.

Executive Summary
In this Management’s Discussion and Analysis of Financial Condition and Results of Operations section, Altria refers to the following “adjusted” financial measures: adjusted operating companies income (loss) (“OCI”); adjusted OCI margins; adjusted net earnings attributable to Altria; adjusted diluted earnings (losses) per share (“EPS”) attributable to Altria; and adjusted effective tax rates. These adjusted financial measures are not required by, or calculated in accordance with, United States generally accepted accounting principles (“GAAP”) and may not be calculated the same as similarly titled measures used by other companies. These adjusted financial measures should thus be considered as supplemental in nature and not considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. Except as noted in 2021 Forecasted Results section below, when Altria provides a non-GAAP measure in this Form 10-K, it also provides a reconciliation of that non-GAAP financial measure to the most directly comparable GAAP financial measure. For a further description of these non-GAAP financial measures, see the Non-GAAP Financial Measures section below.
COVID-19 Pandemic
The COVID-19 pandemic has led to adverse impacts on the U.S. and global economies and continues to create economic uncertainty. Although much uncertainty still surrounds the pandemic, including its duration and ultimate overall impact on U.S. and global economies, its subsidiaries’ operations and those of Altria’s investees, Altria continues to monitor the macroeconomic risks of the COVID-19 pandemic and continues to carefully evaluate potential outcomes and work to mitigate risks. Specifically, Altria remains focused on any potential impact to its liquidity, operations, supply and distribution chains and on economic conditions.
In terms of Altria’s liquidity, despite some volatility in the commercial paper market in March 2020, Altria was able to build and maintain a higher cash balance than normal to preserve its financial flexibility. As a precautionary measure, in March 2020, Altria borrowed the full $3.0 billion available under its senior unsecured 5-year revolving credit agreement (as amended, the “Credit Agreement”), which Altria subsequently repaid in full in June 2020. In May 2020, Altria issued $2.0 billion of long-term debt in the form of senior unsecured notes. In April 2020, the Board of Directors rescinded the $500 million remaining in the previously authorized $1.0 billion share repurchase program. Altria did not repurchase any shares under its share repurchase program in 2020.
As with so many other companies throughout the U.S. and globally, Altria’s operations have been affected by the COVID-19 pandemic. Altria has implemented remote working for many employees and aligned with the social distancing protocols recommended by public

17

Table of Contents
health authorities. To date, Altria believes its tobacco businesses have not experienced any material adverse effects associated with governmental actions to restrict consumer movement or business operations, but continues to monitor these factors. Altria continues to believe that remote working due to the COVID-19 pandemic has had minimal impact on productivity. Also, Altria’s critical information technology systems have remained operational. Although Altria’s tobacco businesses previously suspended operations temporarily at several of their manufacturing facilities in March 2020, the businesses resumed operations at those facilities under enhanced safety protocols in April 2020 and all manufacturing facilities are currently operational under enhanced safety protocols. Altria continues to monitor the risks associated with facility disruptions and workforce availability as a result of uncertainty related to the COVID-19 pandemic.
Altria’s suppliers and those within its distribution chain are also subject to government actions that may require the closure of a facility and remote working protocols. To date, Altria has not experienced any material disruptions to its supply chains or distribution systems, but is continuing to monitor these factors. The majority of retail stores in which Altria’s tobacco products are sold, including convenience stores, have been deemed to be essential businesses by authorities and have remained open. Altria continues to monitor the risk that one or more suppliers, distributors or any other entities within our supply and distribution chain closes temporarily or permanently.
In March 2020, PM USA temporarily closed its Atlanta and Richmond IQOS stores and paused its IQOS interactive marketing efforts. In June 2020, PM USA re-opened its Atlanta and Richmond IQOS stores, and in July 2020, PM USA launched IQOS in Charlotte, with all stores operating under enhanced safety protocols.
In 2020, Altria incurred net pre-tax charges of $50 million, which were directly related to disruptions caused by or efforts to mitigate the impact of the COVID-19 pandemic. These costs, which were recorded in the second quarter and excluded from Altria’s adjusted results, included premium pay, personal protective equipment and health screenings, partially offset by certain employment tax credits. These net pre-tax charges do not include the inventory-related implementation costs associated with the wine business strategic reset.
Although Altria’s tobacco businesses have not been materially impacted to date by the COVID-19 pandemic, there is continued uncertainty as to how the COVID-19 pandemic may impact adult tobacco consumers in the future. Altria continues to monitor the macroeconomic risks of the COVID-19 pandemic and their effect on adult tobacco consumers, including stay-at-home practices and disposable income (which may be impacted by unemployment rates and fiscal stimulus). Altria also continues to monitor adult tobacco consumers’ purchasing behaviors, including overall tobacco product expenditures, mix between premium and discount brand purchases and adoption of non-combustible products.
While Altria’s tobacco businesses have not been materially impacted to date by the COVID-19 pandemic, Altria has experienced adverse impacts to its alcohol assets. In the wine business, Ste. Michelle’s direct-to-consumer sales and on-premise wine sales in restaurants, bars and hospitality venues and on cruise lines have been, and continue to be, negatively impacted by disruptions arising from the COVID-19 pandemic, which also may have an impact on adult wine consumers going forward. In 2020, against a backdrop of product volume demand uncertainty and long-term, non-cancelable grape purchase commitments, which have been further negatively impacted by the COVID-19 pandemic (including economic uncertainty and government actions that restrict direct-to-consumer sales and on-premise sales), Ste. Michelle recorded pre-tax charges of $411 million consisting primarily of (i) the write-off of inventory and (ii) estimated losses on future non-cancelable grape purchase commitments. Altria and Ste. Michelle also undertook a review of the wine business resulting in a strategic reset. Ste. Michelle continues to monitor the impact of the COVID-19 pandemic associated risks to its business, results of operations, cash flows and financial position.
ABI has also been impacted by the COVID-19 pandemic, including (i) a 50% reduction to its final 2019 dividend paid in the second quarter of 2020 and a decision to forgo its interim 2020 dividend that would have been paid in the fourth quarter of 2020; (ii) the withdrawal of its guidance for 2020 due to the uncertainty, volatility and impact of the COVID-19 pandemic; and (iii) a goodwill impairment charge related to its Africa businesses in 2020. In addition, the extreme market disruption and volatility associated with the COVID-19 pandemic resulted in a steep decline in ABI’s stock price in the first half of 2020. Although there was a gradual recovery in ABI’s stock price in the second half of 2020, the fair value of Altria’s investment in ABI is below the carrying value. While Altria believes that this decline is temporary, it will continue to monitor its investment in ABI, including the impact of the COVID-19 pandemic on ABI’s business and market valuation.
Altria considered the impact of the COVID-19 pandemic on the business of JUUL, including its sales, distribution, operations, supply chain and liquidity, in conducting its periodic impairment assessment and quantitative valuations. While the impact of the COVID-19 pandemic was considered in our quantitative valuations during the year ended December 31, 2020, Altria does not believe the COVID-19 pandemic was a primary driver of the non-cash pre-tax impairment charge of $2.6 billion recorded during the three months ended September 30, 2020 or the $100 million increase in fair value during the three months ended December 31, 2020. Altria will continue to monitor the impact of the COVID-19 pandemic on JUUL’s business in our quarterly valuations of JUUL.
Altria has considered the impact of the COVID-19 pandemic on the business of Cronos, including its sales, distribution, operations, supply chain and liquidity. Cronos has been and continues to be impacted by the COVID-19 pandemic, due in part to government action requiring closures or limited occupancy of retail stores in the United States. During the second quarter of 2020, Cronos recorded an impairment charge on goodwill and intangible assets as a result of the impact of the COVID-19 pandemic (which Altria recorded in the

18

Table of Contents
third quarter of 2020 due to its one-quarter lag in reporting Cronos’s results). Altria will continue to monitor its investment in Cronos, including the impact of the COVID-19 pandemic on Cronos’s business and market valuation.

Consolidated Results of Operations
The changes in net earnings (losses) and diluted EPS attributable to Altria for the year ended December 31, 2020, from the year ended December 31, 2019, were due primarily to the following:
(in millions, except per share data)Net Earnings (Losses)Diluted EPS
For the year ended December 31, 2019$(1,293)$(0.70)
2019 Asset impairment, exit, implementation and acquisition-related costs269 0.15 
2019 Tobacco and health litigation items58 0.03 
2019 Impairment of JUUL equity securities8,600 4.60 
2019 ABI-related special items (1)
(303)(0.16)
2019 Cronos-related special items640 0.34 
2019 Tax items(99)(0.05)
Subtotal 2019 special items9,165 4.91 
2020 NPM Adjustment Items(3)— 
2020 Asset impairment, exit, implementation and acquisition-related costs(342)(0.18)
2020 Tobacco and health litigation items(62)(0.03)
2020 Impairment of JUUL equity securities(2,600)(1.40)
2020 JUUL changes in fair value100 0.05 
2020 ABI-related special items(603)(0.32)
2020 Cronos-related special items(53)(0.03)
2020 COVID-19 special items(37)(0.02)
2020 Tax items(50)(0.03)
Subtotal 2020 special items(3,650)(1.96)
Fewer shares outstanding 0.02 
Change in tax rate(108)(0.06)
Operations353 0.19 
For the year ended December 31, 2020$4,467 $2.40 
2020 Reported Net Earnings (Losses)$4,467 $2.40 
2019 Reported Net Earnings (Losses)$(1,293)$(0.70)
% Change100%+100%+
2020 Adjusted Net Earnings and Adjusted Diluted EPS$8,117 $4.36 
2019 Adjusted Net Earnings and Adjusted Diluted EPS (1)
$7,872 $4.21 
% Change3.1 %3.6 %
(1) Prior period amounts have been recast to conform with current period presentation for certain ABI mark-to-market adjustments that were not previously identified as special items and that are now excluded from Altria’s adjusted financial measures. For further discussion, see below.

For a discussion of special items and other business drivers affecting the comparability of statements of earnings (losses) amounts and reconciliations of adjusted earnings attributable to Altria and adjusted diluted EPS attributable to Altria, see the Consolidated Operating Results section below.
Fewer Shares Outstanding: Fewer shares outstanding during 2020 compared with 2019 were due primarily to the timing of shares repurchased by Altria in 2019 under its share repurchase program.
Change in Tax Rate: The change in tax rate (which excludes the impact of tax items shown above) was driven primarily by lower dividends from ABI.

19

Table of Contents
Operations: The increase of $353 million in operations (which excludes the impact of special items shown above) was due primarily to the following:
higher income from the smokeable products and oral tobacco products segments;
partially offset by:
lower income from Altria’s equity investments in ABI and Cronos;
higher losses in the all other category (primarily driven by reductions in the estimated residual values of certain assets at PMCC in 2020);
higher amortization expense;
higher interest and other debt expense, net; and
lower income from the wine segment.
For further details, see the Consolidated Operating Results and Operating Results by Business Segment sections below.
2021 Forecasted Results
Altria forecasts its 2021 full-year adjusted diluted EPS to be in a range of $4.49 to $4.62, representing a growth rate of 3% to 6% over its 2020 full-year adjusted diluted EPS base of $4.36, as shown in the table below. While the 2021 full-year adjusted diluted EPS guidance accounts for a range of scenarios, the external environment remains dynamic. Altria will continue to monitor conditions related to (i) unemployment rates, (ii) fiscal stimulus, (iii) adult tobacco consumer dynamics, including stay-at-home practices, disposable income, purchasing patterns and adoption of non-combustible products, (iv) regulatory and legislative (including excise tax) developments, (v) the timing and breadth of COVID-19 vaccine deployment and (vi) expectations for adjusted earnings contributions from its alcohol assets.
Altria’s 2021 full-year adjusted diluted EPS guidance range includes planned investments in support of its Vision, such as (i) marketplace investments to expand the availability and awareness of Altria’s non-combustible products, (ii) costs associated with building an industry-leading consumer engagement platform that enhances data collection and insights in support of adult tobacco consumer conversion to non-combustible products and (iii) increased non-combustible product research and development expense. Altria expects 2021 adjusted diluted EPS growth to come in the last three quarters of the year, primarily due to prior year comparisons, including one fewer shipping day for the smokeable products segment in the first quarter.
This forecasted growth rate excludes estimated per share charges in the first quarter of 2021 of $0.27 for loss on early extinguishment of debt for the February 2021 Tender Offers and Redemption. For further discussion, see Financial Review - Debt and Liquidity - Debt below.
Altria expects its 2021 full-year adjusted effective tax rate will be in a range of 24.5% to 25.5%.
Reconciliation of 2020 Reported Diluted EPS to 2020 Adjusted Diluted EPS
2020 Reported diluted EPS$2.40 
Asset impairment, exit, implementation and acquisition-related costs 0.18 
Tobacco and health litigation items0.03 
Impairment of JUUL equity securities1.40 
JUUL changes in fair value(0.05)
ABI-related special items0.32 
Cronos-related special items0.03 
COVID-19 special items0.02 
Tax items 0.03 
2020 Adjusted diluted EPS$4.36 
For a discussion of certain income and expense items excluded from the forecasted results above, see the Consolidated Operating Results section below.
Altria’s full-year adjusted diluted EPS guidance and full-year forecast for its adjusted effective tax rate exclude the impact of certain income and expense items, including those items noted in the Non-GAAP Financial Measures section below, that management believes are not part of underlying operations. Altria’s management cannot estimate on a forward-looking basis the impact of these items on its reported diluted EPS or its reported effective tax rate because these items, which could be significant, may be unusual or infrequent, are difficult to predict and may be highly variable. As a result, Altria does not provide a corresponding GAAP measure for, or reconciliation to, its adjusted diluted EPS guidance or its adjusted effective tax rate forecast.

20

Table of Contents
Non-GAAP Financial Measures
While Altria reports its financial results in accordance with GAAP, its management also reviews certain financial results, including OCI, OCI margins, net earnings (losses) attributable to Altria and diluted EPS, on an adjusted basis, which excludes certain income and expense items that management believes are not part of underlying operations. These items may include, for example, loss on early extinguishment of debt, restructuring charges, asset impairment charges, acquisition-related costs, COVID-19 special items, equity investment-related special items (including any changes in fair value of the equity investment and any related warrants and preemptive rights), certain tax items, charges associated with tobacco and health litigation items, and resolutions of certain non-participating manufacturer (“NPM”) adjustment disputes under the 1998 Master Settlement Agreement (such dispute resolutions are referred to as “NPM Adjustment Items”). Altria’s management does not view any of these special items to be part of Altria’s underlying results as they may be highly variable, may be unusual or infrequent, are difficult to predict and can distort underlying business trends and results. Altria’s management also reviews income tax rates on an adjusted basis. Altria’s adjusted effective tax rate may exclude certain tax items from its reported effective tax rate.
Altria’s management believes that adjusted financial measures provide useful additional insight into underlying business trends and results, and provide a more meaningful comparison of year-over-year results. Adjusted financial measures are used by management and regularly provided to Altria’s chief operating decision maker (“CODM”) for planning, forecasting and evaluating business and financial performance, including allocating resources and evaluating results relative to employee compensation targets. These adjusted financial measures are not required by, or calculated in accordance with GAAP and may not be calculated the same as similarly titled measures used by other companies. These adjusted financial measures should thus be considered as supplemental in nature and not considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP.
Discussion and Analysis
Critical Accounting Policies and Estimates
Note 2 includes a summary of the significant accounting policies and methods used in the preparation of Altria’s consolidated financial statements. In most instances, Altria must use an accounting policy or method because it is the only policy or method permitted under GAAP.
The preparation of financial statements includes the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of net revenues and expenses during the reporting periods. If actual amounts are ultimately different from previous estimates, the revisions are included in Altria’s consolidated results of operations for the period in which the actual amounts become known. Historically, the aggregate differences, if any, between Altria’s estimates and actual amounts in any year have not had a significant impact on its consolidated financial statements.
The following is a review of the more significant assumptions and estimates, as well as the accounting policies and methods, used in the preparation of Altria’s consolidated financial statements:
Consolidation: The consolidated financial statements include Altria, as well as its wholly owned and majority-owned subsidiaries. Investments in equity securities in which Altria has the ability to exercise significant influence over the operating and financial policies of the investee are accounted for either under the equity method of accounting or the fair value option. Investments in equity securities that Altria does not have the ability to exercise significant influence over the operating and financial policies of the investee are accounted for as an investment in an equity security. All intercompany transactions and balances have been eliminated.
Revenue Recognition: Altria’s businesses generate substantially all of their revenue from sales contracts with customers. While Altria’s businesses enter into separate sales contracts with each customer for each product type, all sales contracts are similarly structured. These contracts create an obligation to transfer product to the customer. All performance obligations are satisfied within one year; therefore, costs to obtain contracts are expensed as incurred and unsatisfied performance obligations are not disclosed. There is no financing component because Altria’s businesses expect, at contract inception, that the period between when Altria’s businesses transfer product to the customer and when the customer pays for that product will be one year or less.
Altria’s businesses define net revenues as revenues, which include excise taxes and shipping and handling charges billed to customers, net of cash discounts for prompt payment, sales returns (also referred to as returned goods) and sales incentives. Altria’s businesses exclude from the transaction price sales taxes and value-added taxes imposed at the time of sale (which do not include excise taxes on cigarettes, cigars, smokeless tobacco or wine billed to customers).
Altria’s businesses recognize revenues from sales contracts with customers upon shipment of goods when control of such products is obtained by the customer. Altria’s businesses determine that a customer obtains control of the product upon shipment when title of such product and risk of loss transfers to the customer. Altria’s businesses account for shipping and handling costs as fulfillment costs and such amounts are classified as part of cost of sales in Altria’s consolidated statements of earnings (losses). Altria’s businesses record an allowance for returned goods, based principally on historical volume and return rates, which is included in other accrued liabilities on Altria’s consolidated balance sheets. Altria’s businesses record sales incentives, which consist of consumer incentives and trade promotion activities, as a reduction to revenues (a portion of which is based on amounts estimated as being due to wholesalers, retailers

21

Table of Contents
and consumers at the end of a period) based principally on historical volume, utilization and redemption rates. Expected payments for sales incentives are included in accrued marketing liabilities on Altria’s consolidated balance sheets.
Payment terms vary depending on product type. Altria’s businesses consider payments received in advance of product shipment as deferred revenue, which is included in other accrued liabilities on Altria’s consolidated balance sheets until revenue is recognized. PM USA receives payment in advance of a customer obtaining control of the product. USSTC receives substantially all payments within one business day of the customer obtaining control of the product. Ste. Michelle receives substantially all payments from customers within 45 days of the customer obtaining control of the product. Amounts due from customers are included in receivables on Altria’s consolidated balance sheets.
For further discussion, see Note 3. Revenues from Contracts with Customers to the consolidated financial statements in Item 8.
Depreciation, Amortization, Impairment Testing and Asset Valuation: Altria depreciates property, plant and equipment and amortizes its definite-lived intangible assets using the straight-line method over the estimated useful lives of the assets. Machinery and equipment are depreciated over periods up to 25 years, and buildings and building improvements over periods up to 50 years. Definite-lived intangible assets are amortized over their estimated useful lives up to 25 years.
Altria reviews long-lived assets, including definite-lived intangible assets, for impairment whenever events or changes in business circumstances indicate that the carrying value of the assets may not be fully recoverable. Altria performs undiscounted operating cash flow analyses to determine if an impairment exists. These analyses are affected by general economic conditions and projected growth rates. For purposes of recognition and measurement of an impairment for assets held for use, Altria groups assets and liabilities at the lowest level for which cash flows are separately identifiable. If Altria determines that an impairment exists, any related impairment loss is calculated based on fair value. Impairment losses on assets to be disposed of, if any, are based on the estimated proceeds to be received, less costs of disposal. Altria also reviews the estimated remaining useful lives of long-lived assets whenever events or changes in business circumstances indicate the lives may have changed.
Altria conducts a required annual review of goodwill and indefinite-lived intangible assets for potential impairment, and more frequently if an event occurs or circumstances change that would require Altria to perform an interim review. Altria has the option of first performing a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit or indefinite-lived intangible asset is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative impairment test. If necessary, Altria will perform a single step quantitative impairment test. Additionally, Altria has the option to unconditionally bypass the qualitative assessment and perform a single step quantitative assessment. If the carrying value of a reporting unit that includes goodwill exceeds its fair value, which is determined using discounted cash flows, goodwill is considered impaired. The amount of impairment loss is measured as the difference between the carrying value and the fair value of a reporting unit, but is limited to the total amount of goodwill allocated to a reporting unit. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, which is determined using discounted cash flows, the intangible asset is considered impaired and is reduced to fair value in the period identified.
Goodwill by reporting unit and indefinite-lived intangible assets at December 31, 2020 were as follows:
(in millions)GoodwillIndefinite-Lived
Intangible Assets
Cigarettes$22 $2 
MST and snus products5,023 8,801 
Cigars77 2,640 
Wine 233 
Oral nicotine pouches55  
Total$5,177 $11,676 
During 2020, Altria completed its annual impairment test of goodwill and indefinite-lived intangible assets performed as of October 1, 2020 and the results of this testing were as follows:
no impairment charges were recorded;
the estimated fair values of the cigarettes, cigars and oral nicotine pouches reporting units and the indefinite-lived intangible assets within the cigars reporting unit substantially exceeded their carrying values;
the estimated fair values of the MST and snus products reporting unit and the indefinite-lived intangible assets within the reporting unit substantially exceeded their carrying values, with the exception of the Skoal trademark. Skoal continues to be impacted by increased competition as well as adult tobacco consumer movement among tobacco products, including oral nicotine pouch products. At December 31, 2020, the estimated fair value of the Skoal trademark exceeded its carrying value of $3.9 billion by approximately 28%, which is an increase from approximately 18% at December 31, 2019. This increase is due primarily to a decrease in the discount rate resulting from changes in market inputs. Altria believes an increase in the future

22

Table of Contents
discount rate in isolation, which could be caused by numerous factors, including changes in market inputs, as well as the specific risks associated with the Skoal business, could have the potential to materially decrease the future estimated fair value of the Skoal trademark. A 1% increase in the discount rate would have resulted in the estimated fair value exceeding its carrying value by approximately 13% at December 31, 2020; and
the estimated fair values of the indefinite-lived intangible assets within the wine reporting unit substantially exceeded their carrying values, with the exception of the Patz & Hall trademark, which at December 31, 2020, exceeded its carrying value of $30 million by approximately 6%.
During 2019, Altria’s quantitative annual impairment test of goodwill and indefinite-lived intangible assets resulted in $74 million of impairment charges. During 2018, Altria’s quantitative annual impairment test of goodwill and indefinite-lived intangible assets resulted in $54 million of impairment charges. For further discussion on goodwill, see Note 4. Goodwill and Other Intangible Assets, net to the consolidated financial statements in Item 8 (“Note 4”).
In 2020, Altria elected to perform a qualitative assessment for certain of its reporting units and indefinite-lived intangible assets. This qualitative assessment included the review of certain macroeconomic factors and entity-specific qualitative factors to determine if it was more-likely-than-not that the fair values of its reporting units were below carrying value. For certain of its other reporting units and indefinite-lived intangible assets, Altria elected to unconditionally bypass the qualitative assessment and perform a single step quantitative assessment. Altria used an income approach to estimate the fair values of all of its reporting units and indefinite-lived intangible assets. The income approach reflects the discounting of expected future cash flows to their present value at a rate of return that incorporates the risk-free rate for the use of those funds, the expected rate of inflation and the risks associated with realizing expected future cash flows. The weighted-average discount rate used in performing the valuations was approximately 10%.
In performing the 2020 discounted cash flow analysis, Altria made various judgments, estimates and assumptions, the most significant of which were volume, income, growth rates and discount rates. The analysis incorporated assumptions used in Altria’s long-term financial forecast, which is used by Altria’s management to evaluate business and financial performance, including allocating resources and evaluating results relative to setting employee compensation targets. The assumptions incorporated the highest and best use of Altria’s indefinite-lived intangible assets and also included perpetual growth rates for periods beyond the long-term financial forecast. The perpetual growth rate used in performing all of the valuations was 2%. Fair value calculations are sensitive to changes in these estimates and assumptions, some of which relate to broader macroeconomic conditions outside of Altria’s control.
Although Altria’s discounted cash flow analysis is based on assumptions that are considered reasonable and based on the best available information at the time that the discounted cash flow analysis is developed, there is significant judgment used in determining future cash flows. The following factors have the most potential to impact expected future cash flows and, therefore, Altria’s impairment conclusions: general economic conditions (such as continued uncertainty from the COVID-19 pandemic); federal, state and local regulatory developments; category growth rates; consumer preferences; success of planned new product expansions; competitive activity; and income and excise taxes. For further discussion of these factors, see Operating Results by Business Segment - Tobacco Space - Business Environment and Operating Results by Business Segment - Wine Segment - Business Environment below.
While Altria’s management believes that the estimated fair values of each reporting unit and indefinite-lived intangible asset at December 31, 2020 are reasonable, actual performance in the short-term or long-term could be significantly different from forecasted performance, which could result in impairment charges in future periods.
For further discussion of goodwill and other intangible assets, see Note 4.
Investments in Equity Securities: Altria reviews its equity investments accounted for under the equity method of accounting for impairment by comparing the fair value of each of its investments to their carrying value. If the carrying value of an investment exceeds its fair value and the loss in value is other than temporary, the investment is considered impaired and reduced to fair value, and the impairment is recognized in the period identified. The factors used to make this determination include the duration and magnitude of the fair value decline, the financial condition and near-term prospects of the investee, and Altria’s intent and ability to hold its investment until recovery.
Following Share Conversion in the fourth quarter of 2020, Altria elected to account for its equity investment in JUUL under the fair value option. Under this option, any cash dividends received and any changes in the fair value of the equity investment in JUUL, which is calculated quarterly using level 3 fair value measurements, are included in income (losses) from equity investments in the consolidated statements of earnings (losses). The fair value of the equity investment in JUUL is included in investments in equity securities on the consolidated balance sheet at December 31, 2020. Altria believes the fair value option provides quarterly transparency to investors as to the fair market value of Altria’s investment in JUUL, given the changes and volatility in the e-vapor category since Altria’s initial investment, as well as the lack of publicly available information regarding JUUL’s business or a market-derived valuation.
Prior to Share Conversion, Altria accounted for its investment in JUUL as an investment in an equity security. Since the JUUL shares did not have a readily determinable fair value, Altria elected to measure its investment in JUUL at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Altria reviewed its investment in JUUL for impairment by performing a qualitative assessment of impairment indicators on a

23

Table of Contents
quarterly basis in connection with the preparation of its financial statements. If this qualitative assessment indicated that Altria’s investment in JUUL may be impaired, a quantitative assessment was performed. If the quantitative assessment indicated the fair value of the investment is less than its carrying value, the investment was written down to its fair value, and the impairment was recognized in the period identified. The impairment charges Altria recorded related to its Investment in JUUL are included in impairment of JUUL equity securities in the consolidated statements of earnings (losses).
Investment in ABI
At December 31, 2020, Altria’s investment in ABI consisted of 185 million restricted shares of ABI (the “Restricted Shares”) and 12 million ordinary shares of ABI. The fair value of Altria’s equity investment in ABI is based on: (i) unadjusted quoted prices in active markets for ABI’s ordinary shares and was classified in Level 1 of the fair value hierarchy and (ii) observable inputs other than Level 1 prices, such as quoted prices for similar assets, for the Restricted Shares, and was classified in Level 2 of the fair value hierarchy. Altria may, in certain instances, pledge or otherwise grant a security interest in all or part of its Restricted Shares. In the event the pledgee or security interest holder were to foreclose on the Restricted Shares, the encumbered Restricted Shares will be automatically converted, one-for-one, into ordinary shares. Therefore, the fair value of each Restricted Share is based on the value of an ordinary share.
The fair value of Altria’s equity investment in ABI at December 31, 2020 and 2019 was $13.8 billion (carrying value of $16.7 billion) and $16.1 billion (carrying value of $18.1 billion), respectively, which was less than its carrying value by approximately 17% and 11%, respectively, at December 31, 2020 and 2019. At February 22, 2021, the fair value of Altria’s investment decreased to approximately $12.8 billion. In October 2019, the fair value of Altria’s equity investment in ABI declined below its carrying value and has not recovered. Altria has evaluated the factors related to the fair value decline, including the recent impact on the fair value of ABI’s shares during the COVID-19 pandemic, which has negatively impacted ABI’s business. Altria has evaluated the duration and magnitude of the fair value decline at December 31, 2020, ABI’s financial condition and near-term prospects, and Altria’s intent and ability to hold its investment in ABI until recovery. Altria concluded, both at December 31, 2020 and 2019, that the decline in fair value of its investment in ABI below its carrying value was temporary and, therefore, no impairment was recorded. This conclusion was based on the following factors:
the fair value of Altria’s equity investment in ABI historically exceeding its carrying value since October 2016, when Altria obtained its ownership interest in ABI, with the exception of certain periods starting in September 2018;
a history of significant recovery in stock price during 2019, as well as an increase from March 31, 2020 to February 22, 2021, which Altria believes indicates investor confidence in ABI’s ability to implement its business strategies and deleveraging plans;
the continued industry disruption and volatility associated with the COVID-19 pandemic, resulting in stock performance among ABI competitors that Altria does not believe are reflective of actual underlying equity values;
ABI’s recent proactive actions to preserve financial flexibility and commitment to its long-term deleveraging initiative, including the following actions since December 31, 2019: (i) ABI’s 50% reduction to its final 2019 dividend paid in the second quarter of 2020 and its decision to forgo its interim 2020 dividend that would have been paid in the fourth quarter of 2020; (ii) ABI’s completion of the sale of its Australia subsidiary in the second quarter of 2020 for $11 billion in cash proceeds; (iii) ABI’s continuation of its refinancing efforts through issuance and redemption activity, specifically front-end maturities into longer dated maturities; and (iv) ABI’s completion of the sale of a minority stake in its U.S.-based metal container plants in the fourth quarter of 2020 for $3 billion in cash proceeds;
ABI’s global platform (world’s largest brewer by volume and one of the world’s top ten consumer products companies by revenue) with strong market positions in key markets, new product innovations, geographic diversification, experienced management team, strict financial discipline (cost management and efficiency) and expected earnings and history of performance; and
the strategic plans implemented by ABI in response to the adverse impacts of the COVID-19 pandemic, including its ability to leverage learnings from recovering markets and respond quickly to the evolving environment to better position ABI for a robust recovery. This was evidenced by ABI’s performance in the second half of 2020, which represented improvement over the first half of 2020 and reinforced its confidence in the future potential of the beer category and its business. Additionally, as ABI stated in its year-end 2020 earnings report, it expects financial results in 2021 to improve meaningfully versus 2020. Additionally, ABI states its 2021 outlook reflects among other factors, its current assessment of the scale and magnitude of the COVID-19 pandemic, which is subject to change as it continues to monitor ongoing developments.
Altria will continue to monitor its investment in ABI, including the impact of the COVID-19 pandemic and subsequent recovery on ABI’s business and market valuation. If Altria were to conclude that the decline in fair value is other than temporary, Altria would determine and recognize, in the period identified, the impairment of its investment, which could result in a material adverse effect on Altria’s consolidated financial position or earnings.
Investment in JUUL
In 2020, Altria recorded a: (i) non-cash pre-tax impairment charge of $2.6 billion for three months ended September 30, 2020 related to its investment in JUUL and (ii) non-cash pre-tax unrealized gain of $100 million for the fourth quarter and year ended December 31,

24

Table of Contents
2020 as a result of an increase in the fair value of JUUL. The carrying value of Altria’s investment in JUUL was $1.7 billion at December 31, 2020.
In 2019, Altria recorded total non-cash pre-tax impairment charges of $8.6 billion ($4.5 billion in the third quarter of 2019 and $4.1 billion in the fourth quarter of 2019) related to its investment in JUUL resulting in a $4.2 billion carrying value of its investment in JUUL at December 31, 2019.
Altria uses an income approach to estimate the fair value of its investment in JUUL. The income approach reflects the discounting of future cash flows for the U.S. and international markets at a rate of return that incorporates the risk-free rate for the use of those funds, the expected rate of inflation and the risks associated with realizing future cash flows. Future cash flows are based on a range of scenarios that consider various potential regulatory and market outcomes.
In determining the fair value of its investment in JUUL in 2020 and 2019, Altria made various judgments, estimates and assumptions, the most significant of which were sales volume, operating margins, discount rates and perpetual growth rates. All significant inputs used in the valuation are classified in Level 3 of the fair value hierarchy. The discount rates used in performing the valuations ranged from 13.5% to 16.5% at September 30, 2019, 19.5% to 23.0% at December 31, 2019, and 17.0% to 20.5% at September 30, 2020 and December 31, 2020. The perpetual growth rates used in performing each valuation ranged from (0.5%) to 0.0%. Additionally in determining these significant assumptions, Altria made judgments regarding the: (i) likelihood and extent of various potential regulatory actions and the continued adverse public perception impacting the e-vapor category and specifically JUUL, (ii) risk created by the number and types of legal cases pending against JUUL, and (iii) expectations for the future state of the e-vapor category including competitive dynamics.
Although Altria’s discounted cash flow analyses were based on assumptions that Altria’s management considered reasonable and were based on the best available information at the time that the analyses were developed, there is significant judgment used in determining future cash flows. If the following factors, in isolation, significantly deviate from current expectations, Altria believes that they have the potential to materially impact Altria’s significant assumptions of sales volume, operating margins, discount rate, and perpetual growth rate, thus potentially materially decreasing Altria’s valuation of its investment in JUUL:
adverse developments related to litigation;
a successful challenge by the FTC in its administrative complaint against Altria and JUUL;
a substantial increase in state and federal e-vapor excise taxes;
adverse publicity due to underage use of e-vapor products and other factors;
unanticipated adverse impacts on JUUL’s relationships with employees, customers, suppliers and other third parties;
unfavorable financial and market performance, including substantial changes in competitive dynamics;
disruption in JUUL’s current and future plans or operations in domestic and international markets; and
unfavorable regulatory and legislative developments at the international, federal, state and local levels such as the potential removal of certain e-vapor products from the market as a result of FDA enforcement action or the potential denial of new tobacco product applications for e-vapor products.
If the following factors, in isolation, significantly deviate from current expectations, Altria believes that they have the potential to materially impact Altria’s significant assumptions of sales volume, operating margins, discount rate, and perpetual growth rate, thus potentially materially increasing Altria’s valuation of its investment in JUUL:
favorable developments related to litigation;
favorable financial and market performance, including substantial changes in competitive dynamics;
improvement of public perception around JUUL and the e-vapor category; and
favorable regulatory and legislative developments at the international, federal, state and local levels such as FDA authorization of future tobacco product applications for JUUL flavored e-vapor products, which are currently not permitted in the market without authorization.
While Altria’s management believes that the recorded value of its investment in JUUL at December 31, 2020 represents its best estimate of the fair value of the investment, JUUL’s actual performance in the short term or long term could be significantly different from forecasted performance due to changes in the factors noted above. Additionally, the value of Altria’s investment in JUUL could be significantly impacted by changes in the discount rate, which could be caused by numerous factors, including changes in market inputs, as well as risks specific to JUUL and its litigation environment.
Investment in Cronos
The fair value of Altria’s equity method investment in Cronos is based on unadjusted quoted prices in active markets for Cronos’s common shares and was classified in Level 1 of the fair value hierarchy. The fair value of Altria’s equity method investment in Cronos

25

Table of Contents
at December 31, 2020 and 2019 was $1.1 billion (carrying value of $1.0 billion) and $1.2 billion (carrying value of $1.0 billion), respectively, which exceeded its carrying value by approximately 8% and 20% at December 31, 2020 and 2019, respectively.
For further discussion of Altria’s investments in ABI, JUUL and Cronos, see Note 6.
Marketing Costs: Altria’s businesses promote their products with consumer incentives, trade promotions and consumer engagement programs. These consumer incentive and trade promotion activities, which include discounts, coupons, rebates, in-store display incentives and volume-based incentives, do not create a distinct deliverable and are, therefore, recorded as a reduction of revenues. Consumer engagement program payments are made to third parties. Altria’s businesses expense these consumer engagement programs, which include event marketing, as incurred and such expenses are included in marketing, administration and research costs in Altria’s consolidated statements of earnings (losses). For interim reporting purposes, Altria’s businesses charge consumer engagement programs and certain consumer incentive expenses to operations as a percentage of sales, based on estimated sales and related expenses for the full year.
Contingencies: As discussed in Note 18 and Item 3, legal proceedings covering a wide range of matters are pending or threatened in various U.S. and foreign jurisdictions against Altria and its subsidiaries, including PM USA and UST and its subsidiaries, as well as their respective indemnitees and Altria’s investees. In 1998, PM USA and certain other U.S. tobacco product manufacturers entered into the 1998 Master Settlement Agreement (the “MSA”) with 46 states and various other governments and jurisdictions to settle asserted and unasserted health care cost recovery and other claims. PM USA and certain other U.S. tobacco product manufacturers had previously entered into agreements to settle similar claims brought by Mississippi, Florida, Texas and Minnesota (together with the MSA, the “State Settlement Agreements”). PM USA’s portion of ongoing adjusted payments and legal fees is based on its relative share of the settling manufacturers’ domestic cigarette shipments, including roll-your-own cigarettes, in the year preceding that in which the payment is due. In addition, PM USA, Middleton and USSTC are subject to quarterly user fees imposed by the FDA as a result of the FSPTCA. Payments under the State Settlement Agreements and the FDA user fees are based on variable factors, such as volume, operating income, market share and inflation, depending on the subject payment. Altria’s subsidiaries account for the cost of the State Settlement Agreements and FDA user fees as a component of cost of sales. Altria’s subsidiaries recorded approximately $4.7 billion, $4.5 billion and $4.5 billion of charges to cost of sales for the years ended December 31, 2020, 2019 and 2018, respectively, in connection with the State Settlement Agreements and FDA user fees.
Altria and its subsidiaries record provisions in the consolidated financial statements for pending litigation when they determine that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. At the present time, while it is reasonably possible that an unfavorable outcome in a case may occur, except to the extent discussed in Note 18 and Item 3: (i) management has concluded that it is not probable that a loss has been incurred in any of the pending tobacco-related cases; (ii) management is unable to estimate the possible loss or range of loss that could result from an unfavorable outcome in any of the pending tobacco-related cases; and (iii) accordingly, management has not provided any amounts in the consolidated financial statements for unfavorable outcomes, if any. Litigation defense costs are expensed as incurred and included in marketing, administration and research costs in the consolidated statements of earnings (losses).
Employee Benefit Plans: Altria provides a range of benefits to certain employees and retired employees, including pension, postretirement health care and postemployment benefits. Altria records annual amounts relating to these plans based on calculations specified by GAAP, which include various actuarial assumptions as to discount rates, assumed rates of return on plan assets, mortality, compensation increases, turnover rates and health care cost trend rates. Altria reviews its actuarial assumptions on an annual basis and makes modifications to the assumptions based on current rates and trends when it is deemed appropriate to do so. Any effect of the modifications is generally amortized over future periods.
Altria recognizes the funded status of its defined benefit pension and other postretirement plans on the consolidated balance sheet and records as a component of other comprehensive earnings (losses), net of deferred income taxes, the gains or losses and prior service costs or credits that have not been recognized as components of net periodic benefit cost. The gains or losses and prior service costs or credits recorded as components of other comprehensive earnings (losses) are subsequently amortized into net periodic benefit cost in future years.
Altria’s discount rate assumptions for its pension and postretirement plans obligations decreased to 2.7% and 2.6%, respectively, at December 31, 2020 from 3.4% for both plans at December 31, 2019, resulting from changes in market inputs. Altria presently anticipates net pre-tax pension and postretirement income of $85 million in 2021 versus net pre-tax expense of $3 million in 2020, excluding amounts in each year related to settlement and curtailment. This anticipated change is due primarily to (i) lower interest costs, driven by the impact of lower discount rates; and (ii) higher expected return on plan assets due to the higher fair value of plan assets at December 31, 2020. This decrease is partially offset by higher amortization of unrecognized losses, driven by the impact of lower discount rates. Assuming no change to the shape of the yield curve, a 50 basis point decrease (increase) in Altria’s discount rates would increase (decrease) Altria’s pension and postretirement expense by approximately $10 million. Similarly, a 50 basis point decrease (increase) in the expected return on plan assets would increase (decrease) Altria’s pension and postretirement expense by approximately $40 million.
For additional information see Note 16. Benefit Plans to the consolidated financial statements in Item 8 (“Note 16”).

26

Table of Contents
Income Taxes: Significant judgment is required in determining income tax provisions and in evaluating tax positions. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities, using enacted tax rates in effect for the year in which the differences are expected to reverse. Altria determines the realizability of deferred tax assets based on the weight of available evidence, that it is more-likely-than-not that the deferred tax asset will not be realized. In reaching this determination, Altria considers all available positive and negative evidence, including the character of the loss, carryback and carryforward considerations, future reversals of temporary differences and available tax planning strategies.
Altria recognizes a benefit for uncertain tax positions when a tax position taken or expected to be taken in a tax return is more-likely-than-not to be sustained upon examination by taxing authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. Altria recognizes accrued interest and penalties associated with uncertain tax positions as part of the provision for income taxes in its consolidated statements of earnings (losses).
Altria recognized income tax benefits and charges in the consolidated statements of earnings (losses) during 2020, 2019 and 2018 as a result of various tax events, including the impact of the Tax Reform Act.
For additional information on income taxes, see Note 14. Income Taxes to the consolidated financial statements in Item 8 (“Note 14”).

Consolidated Operating Results
 For the Years Ended December 31,
(in millions)2020 2019 2018 
Net Revenues:
Smokeable products$23,089 $21,996 $22,297 
Oral tobacco products2,533 2,367 2,262 
Wine614 689 691 
All other(83)58 114 
Net revenues$26,153 $25,110 $25,364 
Excise Taxes on Products:
Smokeable products$5,162 $5,166 $5,585 
Oral tobacco products130 127 131 
Wine19 21 21 
All other1 — — 
Excise taxes on products$5,312 $5,314 $5,737 
Operating Income:
Operating companies income (loss):
Smokeable products$9,985 $9,009 $8,408 
Oral tobacco products1,718 1,580 1,431 
Wine(360)(3)50 
All other(172)(16)(421)
Amortization of intangibles(72)(44)(38)
General corporate expenses(227)(199)(315)
Corporate asset impairment and exit costs1 (1)— 
Operating income$10,873 $10,326 $9,115 
As discussed further in Note 15, the CODM reviews OCI to evaluate the performance of, and allocate resources to, the segments. OCI for the segments is defined as operating income before general corporate expenses and amortization of intangibles. Management believes it is appropriate to disclose this measure to help investors analyze the business performance and trends of the various business segments.

27

Table of Contents
The following table provides a reconciliation of adjusted net earnings (losses) attributable to Altria and adjusted diluted EPS attributable to Altria for the years ended December 31:
(in millions of dollars, except per share data)Earnings (Losses) before Income TaxesProvision for Income TaxesNet Earnings (Losses)Net Earnings (Losses) Attributable
to Altria
Diluted EPS
2020 Reported$6,890 $2,436 $4,454 $4,467 $2.40 
NPM Adjustment Items4 1 3 3  
Asset impairment, exit, implementation and acquisition-related costs
431 89 342 342 0.18 
Tobacco and health litigation items
83 21 62 62 0.03 
Impairment of JUUL equity securities2,600  2,600 2,600 1.40 
JUUL changes in fair value(100) (100)(100)(0.05)
ABI-related special items763 160 603 603 0.32 
Cronos-related special items51 (2)53 53 0.03 
COVID-19 special items50 13 37 37 0.02 
Tax items (50)50 50 0.03 
2020 Adjusted for Special Items$10,772 $2,668 $8,104 $8,117 $4.36 
2019 Reported$766 $2,064 $(1,298)$(1,293)$(0.70)
Asset impairment, exit, implementation and acquisition-related costs
331 62 269 269 0.15 
Tobacco and health litigation items 77 19 58 58 0.03 
Impairment of JUUL equity securities8,600 — 8,600 8,600 4.60 
ABI-related special items (1)
(383)(80)(303)(303)(0.16)
Cronos-related special items928 288 640 640 0.34 
Tax items— 99 (99)(99)(0.05)
2019 Adjusted for Special Items$10,319 $2,452 $7,867 $7,872 $4.21 
2018 Reported$9,341 $2,374 $6,967 $6,963 $3.68 
NPM Adjustment Items(145)(36)(109)(109)(0.06)
Asset impairment, exit, implementation and acquisition-related costs
538 106 432 432 0.23 
Tobacco and health litigation items131 33 98 98 0.05 
ABI-related special items (1)
(16)(3)(13)(13)— 
Loss on ABI/SABMiller business combination33 26 26 0.01 
Tax items— (197)197 197 0.11 
2018 Adjusted for Special Items$9,882 $2,284 $7,598 $7,594 $4.02 
(1) Prior period amounts have been recast to conform with current period presentation for certain ABI mark-to-market adjustments that were not previously identified as special items and that are now excluded from Altria’s adjusted financial measures.
The following special items affected the comparability of statements of earnings (losses) amounts.
NPM Adjustment Items: For a discussion of NPM Adjustment Items and a breakdown of these items by segment, see Health Care Cost Recovery Litigation - NPM Adjustment Disputes in Note 18 and NPM Adjustment Items in Note 15, respectively.
Asset Impairment, Exit, Implementation and Acquisition-Related Costs: Pre-tax asset impairment, exit, implementation and acquisition-related costs were $431 million, $331 million and $538 million for the years ended December 31, 2020, 2019 and 2018, respectively.
For further discussion on asset impairment, exit and implementation costs, including a breakdown of these costs by segment, see Note 5.

28

Table of Contents
For the years ended December 31, 2020 and 2019, Altria also recorded pre-tax acquisition-related costs of $24 million and $115 million, respectively. The 2019 costs were primarily for the write-off of debt issuance costs related to Altria’s short-term borrowings under the term loan agreement that Altria entered into in connection with its investments in Cronos and JUUL.
In December 2018, Altria announced a cost reduction program (which included workforce and third-party spending reductions across the businesses) that delivered approximately $600 million in annual cost savings in 2020 and 2019. The program was completed in 2019.
In October 2016, Altria announced the consolidation of certain of its operating companies’ manufacturing facilities to streamline operations and achieve greater efficiencies. The consolidation was completed in the first quarter of 2018 and delivered Altria’s goal of approximately $50 million in annualized cost savings as of December 31, 2018.
Tobacco and Health Litigation Items: For a discussion of tobacco and health litigation items and a breakdown of these costs by segment, see Note 18 and Tobacco and Health Litigation Items in Note 15, respectively.
Impairment of JUUL Equity Securities: For the years ended December 31, 2020 and 2019, Altria recorded non-cash pre-tax impairment charges of $2,600 million and $8,600 million, respectively, reported as impairment of JUUL equity securities in its consolidated statements of earnings (losses). A full tax valuation allowance was recorded in 2020 and 2019 attributable to the tax benefit associated with the impairment charges. For further discussion, see Note 6 and Note 14.
JUUL Changes in Fair Value: For the year ended December 31, 2020, Altria recorded a non-cash pre-tax unrealized gain of $100 million reported as (income) losses from equity investments in its consolidated statement of earnings (losses) as a result of an increase in fair value of Altria’s investment in JUUL. A corresponding adjustment was made to the JUUL tax valuation allowance. For further discussion, see Note 6 and Note 14.
ABI-Related Special Items: Altria’s losses from its equity investment in ABI for the year ended December 31, 2020 included net pre-tax charges of $763 million, consisting primarily of Altria’s share of ABI’s (i) mark-to-market losses on certain ABI financial instruments associated with its share commitments, (ii) completion of the sale of its Australia subsidiary and (iii) goodwill impairment charge associated with its Africa businesses.
Altria’s earnings from its equity investment in ABI for the year ended December 31, 2019 included net pre-tax income of $383 million, consisting primarily of a gain related to the completion in September 2019 of ABI’s initial public offering of a minority stake of its Asia Pacific subsidiary and Altria’s share of ABI’s mark-to-market gains on certain ABI financial instruments associated with its share commitments.
Altria’s earnings from its equity investment in ABI for the year ended December 31, 2018 included net pre-tax income of $16 million, consisting primarily of Altria’s share of ABI’s estimated effect of the Tax Reform Act and gains related to ABI’s merger and acquisition activities, partially offset by Altria’s share of ABI’s mark-to-market losses on certain ABI financial instruments associated with its share commitments.
These amounts include Altria’s share of amounts recorded by ABI, and may also include additional adjustments related to (i) conversion from international financial reporting standards to GAAP and (ii) adjustments to Altria’s investment required under the equity method of accounting.
Cronos-Related Special Items: For the years ended December 31, 2020 and 2019, Altria recorded net pre-tax losses of $51 million and $928 million, respectively, consisting of the following:
(in millions)20202019
Loss on Cronos-related financial instruments (1)
$140 $1,442 
(Income) losses from equity investments (2)
(89)(514)
Total Cronos-related special items - (income) expense$51 $928 
(1) The 2020 amount and substantially all of the 2019 amount are related to the non-cash change in the fair value of the warrant and certain anti-dilution protections (the “Fixed-price Preemptive Rights”) acquired in the Cronos transaction.
(2) Amounts primarily include Altria’s share of Cronos’s non-cash change in the fair value of Cronos’s derivative financial instruments associated with the issuance of additional shares.
For further discussion, see Note 6 and Note 7. Financial Instruments to the consolidated financial statements in Item 8.
COVID-19 Special Items: For the year ended December 31, 2020, Altria recorded net pre-tax charges totaling $50 million directly related to disruptions caused by or efforts to mitigate the impact of the COVID-19 pandemic. These net pre-tax charges included premium pay, personal protective equipment and health screenings, partially offset by certain employment tax credits. The COVID-19 special items do not include the charges associated with the wine business strategic reset, which are included in asset, impairment, exit, implementation and acquisition-related costs discussed above. These implementation costs were due to increased inventory levels, which were further negatively impacted by government restrictions and economic uncertainty surrounding the COVID-19 pandemic.

29

Table of Contents
Tax Items: For the year ended December 31, 2020, Altria recorded net tax expense of $50 million, due primarily to net tax expense of $27 million for adjustments resulting from amended returns and audit adjustments related to prior years, and tax expense of $23 million for a tax basis adjustment to Altria’s investment in ABI.
For the year ended December 31, 2019, Altria recorded net tax benefits of $99 million, due primarily to tax benefits of $105 million for adjustments as a result of amended returns and tax benefits of $100 million for the reversal of tax accruals no longer required, partially offset by tax expense of $84 million for a tax basis adjustment to Altria’s equity investment in ABI and $38 million for a valuation allowance on foreign tax credits not realizable.
For the year ended December 31, 2018, Altria recorded net tax expense of $197 million, which included $188 million related to the Tax Reform Act as follows: (i) tax expense of $140 million resulting from a partial reversal of the tax basis benefit associated with the deemed repatriation tax recorded in 2017; (ii) tax expense of $34 million for a valuation allowance on foreign tax credit carryforwards that are not realizable as a result of updates to the provisional estimates recorded in 2017; and (iii) tax expense of $14 million for an adjustment to the provisional estimates for the repatriation tax recorded in 2017.
For further discussion, see Note 14.
2020 Compared with 2019
Net revenues, which include excise taxes billed to customers, increased $1,043 million (4.2%), due to higher net revenues in the smokeable products and oral tobacco products segments, partially offset by lower net revenues in the all other category (primarily driven by reductions in the estimated residual value of certain assets at PMCC in 2020) and the wine segment.